Differentiation of functional human mast cells from adipose derived stem cells and their application in allergo-oncology and the treatment of breast cancer by NC DOCKS at The University of North Carolina at Greensboro & Plotkin, Jesse David
PLOTKIN, JESSE DAVID, Ph.D. Differentiation of Functional Human Mast Cells from 
Adipose Derived Stem Cells and their Application in Allergo-oncology and the 
Treatment of Breast Cancer. (2018) 
Directed by Dr. Christopher Kepley. 136 pp  
 
Mast Cells are important yet poorly understood components of the immune 
system. Study of mast cells has been hampered by difficulty in obtaining primary cells, 
the lack of functional cell lines and the high degree of dissimilarity between human and 
murine mast cells. Adipose derived stem cells are abundant cells in the human body that 
are easily and relatively non-invasively obtained. Using media containing mediators 
secreted by skin derived mast cells, adipose derived stem cells were differentiated into 
functional mast cells. Mast cells differentiated from adipose derived stem cells were 
tested for their ability to respond to and kill cancer cells using an IgE-mediated targeting 
method. Mast cell induced cytotoxicity was observed as well as interactions between 
mast cells and cancer cells. Adipose derived mast cells may represent a platform for 
allergo-oncology.  
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CHAPTER I 
INTRODUCTION 
 
 
Mast cells (MCs) are important immune cells responsible for coordinating 
immune responses such as hypersensitivity, inflammation as well as playing roles in 
wound healing, adipose homeostasis and nociception. Despite being identified well over 
one hundred years ago, MC biology remains shrouded in mystery and debate due to the 
difficulty in obtaining them.  
Since their discovery over one hundred years ago, the association between MCs 
and cancer has been well documented and poorly understood. The association of MCs 
with solid tumors has been appreciated since the initial description of MCs in the 
nineteenth century, indeed Paul Ehrlich himself noted that MCs were commonly 
associated with carcinomas [1] as well as being found by others soon after to be 
associated with all tumor types investigated. [2]. Debate still surrounds the effect of MCs 
on tumors, and whether they contribute to tumor and disease progression or whether they 
constitute part of the immune systems efforts to clear the body of its tumor burden. 
Evidence is mounting, however, that the effect of MCs on cancer is highly context 
dependent, with the nature, location, and mutational burden of the tumor as well as the 
type of MC present, its location within the tumor and the overall inflammatory state of 
the individual bearing the tumor [3]. Due to their highly pleiotropic nature, it is not 
surprising that MCs are not homogeneous in the role in cancer biology and care must be
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taken when considering their use as targets in cancer therapies. While the exact nature of 
the association between MCs and cancer remains a topic of debate, studies correlating the 
presence of MCs in tumors with patient survival outcomes have identified certain types 
of malignancies wherein the presence of MCs seems to be favorable to survivability [4]–
[6]. One of these types of cancer is invasive, HER2 overexpressing breast cancer [7]–[9]. 
The study of MCs and their involvement in cancer is especially difficult given the 
highly heterogeneous and context specific nature of both MC function and cancer 
biology. There is clear evidence for highly detrimental effects of MCs on cancer survival 
and clear protective effects as well. Given the confluence of factors precluding the study 
of MCs in the laboratory, it is hardly surprising, however still somewhat infuriating, that 
they are given short shrift in the field of immuno-oncology. The introduction of a suitable 
source of functional human MCs is essential to understanding and harnessing the full 
potential of MCs in human biology.  
Allergo-oncology refers to the use of IgE to target Fc receptor-bearing cells to 
tumors for the purpose of killing cancer cells in patients. Allergo-oncology is a new 
approach in immunotherapy that relies on the use of IgE rather than IgG as its targeting 
molecule. While there exist, many FDA approved monoclonal antibody therapies, all are 
of the IgG class of immunoglobulins. There are advantages and disadvantages to the use 
of monoclonal IgG-based drugs. The chief disadvantage is danger of triggering the 
patients’ immune system to produce off-target cell, tissue, organ and ultimately system 
damage which in extreme cases can be fatal. Adipose tissue is being used as a source of 
adult stem cells with the goal of providing the MC research community with an 
 
3 
accessible source for cells with which to do research. The purpose of the present study 
was to investigate the viability of using ADMC as a tool for allegro-oncology. In order to 
assess the ability of ADMC to induce cytotoxicity, two mechanisms were investigated, 
Antibody Dependent Cell induced Cytotoxicity (ADCC) and Mediator Induced Cell 
Killing (MICK). Preliminary studies of ADMC-induced cytotoxicity of breast cancer 
cells in vitro are promising and provide a foundation for future animal studies. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
 
 
II.1 Introduction to Mast Cells (MCs) 
In the late 19th century, German microscopist Paul Ehrlich described a type of cell 
in frogs that was identified by the presence of numerous metachromatic granules. Ehrlich 
named these cells “mastzellen” derived from the German word “mast” meaning fattening 
or feed [2], [10]. Found in almost all tissues in the human body, mast cells (MCs) play an 
important role as sentinel cells, sensing and alerting other immune cells to the presence of 
pathogens, particularly parasites. The functions of MCs are diverse and include 
protection against pathogenic infection and coordinating inflammatory actions of effector 
cells in response to foreign bodies. MCs are unique among the immune cells in that they 
participate in both innate and adaptive immunity. In addition to their roles in protection 
from pathogens, MCs serve other important roles in maintaining normal human 
physiology including in wound healing, angiogenesis [10],  and adipocyte maturation 
[11]. While the body of knowledge surrounding MC biology is growing, it is truly 
dwarfed when compared to that of other immune cells. The vast differences in phenotype 
and function between human and rodent MC, human MC lines, and MC obtained from 
tissue sources (e.g. cord blood) has severely hampered basic research on MC biology
[12][13] and is a major impediment to understanding the full role played by MCs in 
health and disease. 
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II.2 Mast Cell Biology 
II.2.i Mast Cell Development 
 The exact nature of MC differentiation in humans remains unclear and while the 
mechanisms of murine MC differentiation are better understood, they are unsatisfactory 
when attempting to understand the analogous human biology.  What is known is that 
MCs like all other hematopoietic cells, arise from hematopoietic stem cells (HSC) in the 
bone marrow [14]. This was demonstrated using a line of beige mice, which exhibit giant 
MC granules and can thus be used as a phenotypic marker, as donors to replace bone 
marrow of an irradiated wild-type mouse [15] and showing that giant granule MCs were 
subsequently observed in the tissues of the irradiated mice. This was later demonstrated 
to also be true in humans using ex vivo culture of human bone marrow cells [16]. 
Hematopoiesis is divided into two lineages, lymphoid and myeloid, of which MCs belong 
to the myeloid lineage, arising from the common myeloid progenitor (CMP). How many 
steps separate the CMP from the mast cell progenitor (MCP) is not known.  
MC progenitors leave the bone marrow and enter the blood stream as agranular, 
CD34+, KIT+, cells [17][18]. A more refined definition of the immature circulating 
progenitor cell that gives rise to tissue MCs is lacking. It has recently been suggested, 
however, that the circulating progenitor may be a relatively rare population of Lin- 
CD34hi CD117int/hi FceRI+ cells [19]. While this is an exciting prospect, more research 
will be required to determine whether this population is in fact the immature, circulating 
form of tissue MCs.	  
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MCP exit the blood stream after an indeterminate period of time and enter tissues 
where they receive cues from the local microenvironment to complete their 
differentiation into mature MCs. It is thought that the major chemotactic signal for MCs 
to enter tissues is stem cell factor (SCF) which is a 245 amino acid protein with a 
membrane-bound and a secreted form, both of which are ligands of c-KIT. Other 
chemokines may also be involved, as there is evidence from mouse studies that disruption 
of some chemokines result in aberrant MC homing [20], but to a lesser extent than SCF. 
SCF serves multiple functions in the progression from circulating progenitor to fully 
differentiated tissue MC. In addition to providing a chemotactic signal, SCF also 
regulates differentiation and maturation of the immature progenitor. c-KIT is a receptor 
tyrosine kinase, upon binding of SCF to the extracellular domain of c-KIT induces 
receptor dimerization which allow the catalytic, cytoplasmic domains to interact and 
cross-phosphorylate multiple tyrosine residues. These phosphorylated cytoplasmic 
domains then serve as binding sites for various other proteins via either an Src homology-
2 or phosphotyrosine-binding domain [20]. A large number of signaling proteins are able 
to bind to activated c-KIT, belonging to several different signaling pathways [21], 
including the phosphatidylinositol-3 kinase, protein kinase C and phospholipase C 
pathways, all of which lead ultimately to phosphorylation cascades terminating in the 
regulation of gene expression. Other pathways that can be induced through c-Kit 
signaling are the Jak/Stat and the Ras/MAPK pathways [20].  Activation of these 
signaling pathways give the immature MC progenitors cues to begin terminal 
differentiation and to begin to localize to tissues. After receiving the appropriate signals 
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for tissue infiltration and differentiation MCs must exit the blood stream and infiltrate 
tissues such as skin, gut and lung mucosa or any sites of inflammation [22][23]. To 
achieve tissue infiltration MCs must first interact with vascular endothelial cells which 
they do via a combination of cell surface adhesion molecules [24]. Human MC 
progenitors produced by in vitro differentiation of cord blood were investigated for their 
ability to bind human umbilical vein endothelial cells under physiological flow and in the 
presence of antibodies for different adhesion molecules. In the context of this assay, these 
MC progenitors were found to have binding inhibited most robustly by antibodies 
blocking their interaction with a4 integrin, vascular adhesion molecule-1 and P-selectin 
glycoprotein ligand-1. In addition to these adhesion molecules, some participation was 
also indicated in other molecules such as integrin b1 and integrin b7. As well as their 
normal migration into tissues as part of their maturation, MCs also respond to 
chemotactic signals originating from sites of inflammation or injury.  
 
II.2.ii Mast Cell Granules 
MC granules are a class of secretory granules (SG) containing preformed immune 
mediators [25]. Due to their low pH, the presence of lysosomal enzymes, and the fact that 
they undergo various other lysosomal functions they are termed lysosome-related 
organelles. MC granules contain a complex and changing complement of factors whose 
exact make up depends upon factors such as anatomical location, disease state and 
presence of xenobiotics. The contents of MC granules can be divided into five major 
categories: 1) enzymes -  predominantly proteases and b-hexosaminidase but also 
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including peroxidase, phospholipase and matrix metalloproteinases, 2) biogenic amines – 
histamine and serotonin, 3) cytokines, 4) proteoglycans – heparin and chondroitin and 5) 
peptides [26]. Tryptase and chymase, two serine-class peptidases, are perhaps the most 
widely studied components of MC granules and are the basis of identification of the two 
major subtypes of human MCs, tryptase-positive (MCT) cells which are found 
predominantly in the gut mucosa and tryptase/chymase-positive (MCTC) cells which are 
found in the skin [27].  
Tryptases are a diverse group of enzymes characterized by their preferred 
substrate, the peptide bond following lysine and arginine found in polypeptides. In 
humans, there are at least six distinct forms of MC tryptase, two of which are inactive, 
arising from four genes, among these six, five are secreted and one is membrane bound. 
There are also several pseudogenes in the human genome that no longer produce 
functional proteins. In MC granules, tryptases are the most abundant proteins, existing in 
oligomeric structures similar to proteasomes. These structures when released into the 
bloodstream are highly resistant to peptidase inhibitors such as a1-anti-trypsin and a2-
macroglobulin and may be stabilized by proteoglycans also found in MC granules [27].  
Chymase is a chymotryptic peptidase found in human MCs, characterized by its preferred 
substrate of the peptide bond following tyrosine and phenylalanine. As mentioned 
previously, chymase is not expressed in all MCs, predominating in cells found in the lung 
and other mucosal tissues. MC chymase arises from a single locus and is present in only 
one form. Chymase is expressed almost exclusively in MCs, however expression has also 
been reported in smooth muscle cells. Cathepsin G is another chymotryptic peptidase 
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found in MC SG. It is characterized by a preference for substrates containing tyrosine and 
phenylalanine as well as amino acids with basic side groups, meaning it also has tryptic 
peptidase-like features. Cathepsin G is not found in MCT type cells [27].    
Another major component of all MC SG is b-hexosaminidase. MCs are peculiar 
with regards to b-hexosaminidase in that it is found predominantly in the SG as opposed 
to the lysosome. b-hexosaminidase is a heterodimeric enzyme present in large amounts in 
lysosomes and in the SG of MCs it is responsible for the cleavage of N-acetylhexosamine 
from N-acetyl-b-hexosaminides, which is an essential part of glycoprotein metabolism 
and therefore general cellular metabolism. The importance of b-hexosaminidase is 
evidenced by the fact that loss of function results in Sandhoff disease, which has far 
reaching effects including blindness, psychosis, and hepatosplenomegaly [28], [29]. 
Furthermore, Fukuishi et al showed that ablation of b-hexosaminidase from the MCs of 
mice prevented clearance of bacteria from the peritoneal cavity [30]. It is hypothesized 
that b-hexosaminidase along with lysozyme is able to disrupt the peptidoglycans present 
in gram positive bacteria. b-hexosaminidase is also important for the study of MCs in that 
it is the most widely used biomarker for MC degranulation. In the eponymously named 
assay, a substrate containing an N-acetylhexosamine (most commonly N-acetyl-b-D-
glucosamine) is incubated with MC supernatant and a colorimetric change is measured.  
Histamine is found in all MC SG, regardless of peptidase content. Histamine is a 
monoamine neurotransmitter and modulator of vascular tone derived from the amino acid 
histidine. Histamine in MC SG is associated with heparin.  
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One of the qualities unique to MCs is the presence of preformed tumor necrosis 
factor alpha (TNF-a) in their secretory granules [31]. TNF-a is released upon stimulation 
of MCs and induces the expression of adhesion molecules on endothelial cells. These 
adhesion molecules are then able to recruit other immune cells associated with the 
inflammatory response such as neutrophils. It has been shown in a rodent leukemic MC 
line that a fusion protein of green fluorescent protein and TNF-a localizes to the 
secretory granule and can be released. It was further demonstrated using inhibitors of 
glycosylation and the sorting of glycoproteins that this process is partially dependent on 
the mannose-6-phosphate receptor and the post-translational modification of N-
glycosylation [32].     
 
II.2.iii IgE Mediated Response 
 MCs respond to IgE through one of three types of IgE receptor, the high affinity 
FceRI receptor, CD23 which is sometimes referred to as the low affinity IgE receptor and 
galectin-3 [33]. FceRI is a tetrameric, membrane receptor whose cognate ligand is the Fc 
domain of IgE. FceRI is critical for triggering the release of granule contents in response 
to allergen [34] as well as beginning a series of secondary processes that allow MCs to 
co-ordinate the inflammatory response. The FceR is composed of three chains, alpha, 
beta and gamma, the tetramer being formed by one alpha, one beta and two gamma 
chains [35]. The ligand binding domain of FceRI is located at the N-terminal of the alpha 
chain and is comprised of two immunoglobulin-related domains which bind Ce2 and Ce3 
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domains in the Fc portion of the IgE molecule. The stoichiometry of binding of IgE: 
FceRI is 1:1 and the affinity of the FceRI for IgE is high, with a Ka on the order of 1010 
M-1 [33]. The fully processed alpha chain is N-glycosylated at seven residues. These 
residues were shown through sequential mutagenesis of the alpha subunit to be required 
for proper folding in the endoplasmic reticulum [36]. The function of the cytoplasmic tail 
of the alpha subunit is poorly understood. The beta and gamma chains are also 
transmembrane proteins, however they do not participate in ligand binding [37]. Both the 
beta and gamma chains possess immunoreceptor tyrosine-based activation motifs 
(ITAMs) which, upon phosphorylation become binding sites for various other signaling 
molecules bearing a Src homology 2 domain, the most well described are Lyn, which 
binds ITAMs on the beta subunit and Syk, which binds ITAMs on the gamma subunit, 
both of which belong to the Src family of kinases.  Activation of these signaling 
molecules can have a wide range of effects depending on the nature of activation 
including degranulation, secondary cytokine and lipid mediator synthesis, increased 
survival and increased receptor expression. In the non-ligand bound state, the ITAMs are 
not phosphorylated and the receptor is not active. In the normal physiological context, 
tissue MCs are found decorated with IgE bound to FceRI receptors. When an antigen 
recognized by IgE molecules on the MCs surface binds two or more IgE molecules, the 
FceRI complexes are brought close together into an aggregated state. Upon aggregation 
Lyn, which has a weak affinity for the ITAM in its unphosphorylated state, is brought in 
close proximity with the beta chains of adjacent receptors in the aggregate which it then 
trans-phosphorylates. The phosphorylated beta chain then induces an increase in the 
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kinase activity of Lyn which leads to the phosphorylation of ITAMs on the gamma 
subunits of the FceRI. The phosphorylated gamma ITAMs are then able to recruit and 
activate Syk molecules. An alternative but very much related pathway for antigen 
induced FceRI activation involves a third Src family kinase, Fyn, which like Lyn binds 
ITAMs on the beta subunit of FceRI. Fyn is also negatively regulated by activated Lyn.       
 
II.2.iv Non-IgE Mediated Response 
 In addition to the IgE-FceRI pathway, MCs can be activated through various other 
pathways due to the very high number and diversity of receptors expressed of their cell 
surface [38]. Among the stimuli for MC activation an important group is those signals 
arising from microorganisms encountered in the human body. These stimuli activate MCs 
through one of a number of possible pathways discussed below. The first class of 
receptors for pathogenic material are the Toll-like receptors of which MCs express at 
least nine [39]. Toll-like receptors are a class of pattern recognition receptors that 
recognize pathogen-associated molecular patterns (PAMPs) contained in certain 
molecules produced by pathogenic organisms such as bacteria and viruses. Of the toll-
like receptors, TLR2, the receptor for peptidoglycans produced by gram-positive bacteria 
and fungi [40], seems to be unique in its ability to induce degranulation upon binding of 
its ligand [41].  TLR4, the receptor for lipopolysaccharide, a molecule produced by gram-
negative bacteria, does not induce degranulation upon binding of its ligand. Instead, 
TLR4 activation leads to the production of a large number of peptide mediators such as 
interleukins, cytokines and chemokines [39] and the non-peptide arachidonic acid 
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derivative mediator cysteinyl leukotriene. In addition to the being able to respond to 
pathogenic microorganisms through the toll-like receptors, another molecule the MC 
possesses that is capable of recognizing pathogens is the C-Type lectin receptor dectin-1. 
The major ligands of dectin-1 are molecules containing the b-1,3-glucan motif [42] as 
found in peptidoglycans from fungi and bacteria. Dectin-1 has a partial ITAM domain in 
its cytoplasmic domain that while not the complete ITAM is able to bind Syk and induce 
the expression of TNF-a as well as several other mediators [42]. The CD2 family 
glycosyl-phosphatidyl-inositol anchored receptor CD48 also contributes to the MCs role 
in pathogen detection through its ligand, FimH, which is a type 1 fimbrial adhesin 
expressed by certain bacteria [43]. CD48 is noteworthy in its ability to induce not only 
degranulation and cytokine production, but also endocytosis of bacterial cells in a 
caveolar-dependent manner [43]. Pattern recognition receptors are not only expressed on 
the cell surface, indeed there are multiple pathways for the detection of intercellular 
pathogens and subsequent activation in response to them. Retinoic acid-inducible gene 1-
like receptors (RLRs) and nucleotide oligomerization domain-like receptors (NLRs) are 
two types of cytoplasmic pattern recognition receptors expressed in MCs. RLRs are 
DExH/D box helicases that bind to double stranded RNA found in the cytoplasm of cells 
infected with certain viruses including the viruses that cause dengue, hepatitis C and  
influenza A [40]. RLRs transduce signals through the caspase recruitment domain 
(CARD) activation of which ultimately leads to induction of NF-kB activity and 
augmentation of gene expression [44]. NLRs possess domains that bind microbial motifs 
[45], an oligomerization domain and a CARD or other similar domain and at least one 
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NLR, Nod1, was shown to be active in MCs [46]. Pattern recognition receptors are an 
important group of molecules, the understanding of which may be important for the 
development of MC related therapies as well as our basic understanding of immune 
surveillance and response to pathogenic invasion. 
In addition to responding to xenobiotics and pathogens, MCs can also be activated 
by a large number of signals from other cells in the body. As is the case with the 
pathogen associated pattern recognition receptors, the pathways leading to MC activation 
by other cells is the product at least in part, of the high diversity of receptors expressed of 
their cell surface [38].  Not surprisingly given their ubiquity in the biology of all 
multicellular organisms, several G protein coupled receptors (GPCRs) are expressed by 
MCs and play roles in the activation of MCs in response to various stimuli. GPCRs are 
seven transmembrane domain proteins that transduce extracellular signals to the cell 
through association with GTP-binding proteins on their cytoplasmic tails. Binding of a 
ligand to the binding pocket of a GPCR leads to the binding of GTP and subsequent 
activation of adenylyl cyclase, which in turn catalyzes the synthesis of the second 
messenger molecule, cyclic AMP (cAMP), which triggers a phosphorylation cascade 
leading to various cellular responses. The majority of ligands for GPCRs expressed on 
MCs are peptides, either neuroregulatory peptides released by neurons, members of the 
complement system or toxins produced by pathogenic organisms [40]. One of these 
classes of GPCRs is relatively newly described and appears to be expressed only on MCs 
and some nervous cell types found in the dorsal root ganglion. This class is made up of 
receptors that bear homology to the oncogene Mas1 and are therefore termed the Mas-
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related GPCRs (MRGs). There are 7 sub-families of MRGs, however only one of these 
subfamilies, the X sub-family, found to be present in humans. Within the X sub-family, 
human MCs are found to express X2 (MRGPRX2). Among the activating ligands of 
MRGPRX2 are substance P, compound 48/80 and vasoactive intestinal peptide [47].  
Another very important group of GPCRs expressed on human MCs are the complement 
receptors. The complement system is a part of the innate immune system that helps to 
target and clear pathogenic organisms from the body. Circulating proteins C5 and C3 are 
proteolytically modified to produce C5a and C3a respectively, which are themselves 
ligands for GPCRs C5aR and C3aR, present on the surface of MCs [48]. Binding of these 
peptides to their receptors on MCs leads to histamine release from the MCs which in turn 
augments the vascular tone of the surrounding vasculature. Similarly to the complement 
factor receptors MCs also express the GPCR for endothelin which also has a potent effect 
on local vascular tone, causing vasoconstriction in the lung and blood vessels and also 
has signaling properties in the cardiac musculature [49]. Binding of endothelin to its 
receptor on MCs induces degranulation of the MCs. This degranulation then sets up an 
inhibitory feedback loop due to the release of inactivating peptidases released from MC 
granules [50].  
One of the molecules responsible for activating MCs in response to signals from 
other cells is the IgG receptor FcgRI [51]. Like FceRI, FcgRI contains a cytoplasmic 
ITAM domain which upon binding of an IgG molecule becomes phosphorylated and 
leads to MC activation. Unlike FceRI however, there is also an inhibitory receptor, 
FcgRIIB, which contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) 
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which upon binding of IgG to the extracellular domain can inhibit activation of MCs 
[43]. 
 
II.3 In vitro Growth and Differentiation of Human MCs  
II.3.i Isolation of Human MCs 
 The isolation of MCs from human tissue was first described over 30 years ago 
[52]–[54]. For example, human skin MCs were isolated from human foreskin removed 
during circumcisions performed on both newborns and adults. In addition to foreskin, 
human MCs were also isolated from lung tissue. These early analyses compared the 
differences between the age of donors and tissue source and began to identify phenotypic 
differences in MCs derived from different tissues. The protocol developed by these 
pioneering researchers has stood largely intact to this day. The basic procedure involves 
mechanically “mincing” the tissue using surgical scissors (Figure 2.1) then digesting it 
with a combination of hyaluronidase, collagenase and DNase in order to disperse cells 
from the remaining intact tissue. Dispersed cell slurries are then filtered to remove any 
undigested connective tissue then subjected to centrifugation on a density gradient 
medium such as Percoll. Density gradient centrifugation is performed in order to remove 
contaminating red blood cells from the cell slurry. Using this method, the researchers at 
the time reported a yield ranging from 200,000 to 1,700,000 cells from every gram of 
tissue used and that these cells were between 3 and 10% pure with respect to MCs (Table 
2.1).    
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Figure 2.1. Mechanical Homogenization of Skin Tissue for MC Extraction. Skin 
tissue is shown in various states of mechanical homogenization by surgical scissors 
and hemostats. Excised tissue (A) is first cleared of subcutaneous adipose tissue (B), 
then cut into cubes (C-D). All procedures are performed in a biological safety 
cabinet as depicted. 
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Table 2.1. Characteristics of Human MC Isolation Protocols. Several MC isolation 
procedures are reviewed, yields are presented in cells per gram and purity in 
percentage. Table was created using data collected from references given. 
 
Study Tissue Source Cells per gram of 
tissue 
Purity 
% 
Reference 
Schwartz et al Foreskin 
(A/N) 
Lung 
200,000 -500,000 
200,000-500,000 
6.7/3.2 
5.1 
47 
Lawrence et 
al 
Foreskin (N) 
Skin (A) 
600,000-1,000,000 
450,000-550,000 
10 
10 
45 
Benyon et al Foreskin 1,500,000-
1,700,000 
5.4 46 
 
 
The cells isolated using this method were investigated for their ability to release 
histamine in response to various stimuli such as anti-IgE, the calcium ionophore A23187, 
compound 48/80, poly-L lysine, morphine, substance P [53], f-MLP peptide and C5a 
[52]. The levels of tryptase and chymase activity in freshly isolated MCs was measured 
using cell extracts and chromogenic substrates [54]. Given the comparative ease of 
obtaining healthy skin from human subjects relative to lung, skin MCs are the most well 
characterized of the primary human MCs. This is discrepancy of ease with which source 
tissue can be obtained is an important one due to the highly heterogeneous nature of MCs 
from different tissues. Great care must be taken not to conflate results obtained with one 
tissue-specific MC type with characteristics common to all MC types. 
These foundational studies laid the groundwork for much of the work that was 
done using MCs isolated from human tissue in their mature form, indeed these three 
papers have been cited over 700 times in the three decades since their initial publication. 
Indispensable as these cells and the methods for their isolation have been to the MC 
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research community, this protocol is not without some considerable drawbacks that must 
be taken into account. The relatively low numbers of mature MCs present in normal 
human tissue is the first problem. Mature MCs have an extremely limited proliferative 
capacity in the human body and in culture [55] and therefore must be expanded once in 
culture or very large amounts of initial tissue must be used, which can be prohibitive 
given that the amount of tissue that is obtained is determined by the needs of the donor 
and thus cannot be dictated by the researcher. The problem of the low numbers of mature 
MCs in tissue is compounded by the relative inefficiency of the isolation method. 
Although this lack of efficiency is difficult to quantify and exact data supporting this 
assertion is lacking, it is the opinion of many practitioners of this protocol that many MCs 
are lost at multiple steps during the isolation procedure (Personal Observation). Another 
limitation of this protocol is necessity of the MC cultures obtained to be further purified 
by long-term culture in serum free media to allow other cell types to die off.  
 
II.3.ii In vitro Differentiation of MC 
 In order to attempt to address some of the technical and biological limitation 
associated with the isolation of fully mature MCs from tissues and also to further the 
knowledge of the developmental biology of the MCs, protocols were also developed for 
the isolation of MC progenitors and the subsequent in vitro differentiation of these cells 
into mature MCs. MC progenitor cells can be obtained from various sources including 
but not limited to CD34+ peripheral blood [18], [56]–[58], blood taken from the umbilical 
cord [59], [60], bone marrow [9][54], dispersed fetal liver [62] [63], or embryonic stem 
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cells [64][65].  The first reports of MCs produced by differentiation of progenitors 
isolated from peripheral blood came from around the same period as those reporting the 
isolation of mature MCs from tissues. Initially, differentiation was achieved through co-
culture of cells isolated from peripheral blood on so-called “feeder” cell monolayers of 
NIH-3T3 mouse embryonic fibroblasts [18]. The progenitor cells used in this study were 
obtained by isolating CD34+ cells from peripheral blood using immune-affinity 
purification using an anti-CD34 antibody. After purification, MC differentiation was 
achieved using IL-3 and SCF. This protocol has since been improved upon by the 
addition of different combinations of differentiating factors, however the basic technique 
has gone largely unchanged. An alternative source of blood for the isolation of MC 
progenitors is blood taken from the umbilical cord of mothers gestating or recently 
birthed newborns [66]. This protocol was also developed around thirty years ago and is 
still in use today [67]. While obvious limitations exist in terms of obtaining cord blood, it 
is nonetheless an interesting source of MC progenitors as it affords the possibility of 
banking cells from the child in question for use in a possible autologous therapy later in 
life [68]. Much like the protocols for differentiating MCs from peripheral blood, the first 
studies relied on NIH-3T3 cells as the source differentiating factors, while subsequently 
developed protocols used recombinant proteins added to the growth media [46]. MC 
progenitors can also be isolated from the bone marrow as it is the location of the primary 
phase of MC development as it is indeed also the site of the beginning of all 
hematopoiesis. Bone marrow in humans is most commonly collected from the iliac crest 
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by means of a biopsy. The utility of fetal liver MCs outside of basic research settings is 
limited due to the nature of obtaining healthy human fetal tissue.  
 
Table 2.2 Differentiation of Human Progenitors into MCs. At least five sources have 
been reported for MC progenitors in humans. The regimens used for differentiation 
are reviewed in brief. 
 
Progenitor 
Source 
Progenitor Cell Morphogens Duration Reference 
Peripheral 
Blood 
CD34+ PBMC SCF, IL-3 21 days [69] 
Umbilical 
Cord Blood 
CD34+ cord 
blood cell 
SCF, Flt-3 ligand, 
thrombopoietin 
4-16 
weeks 
[70] 
Bone Marrow CD34+ bone 
marrow cell 
SCF, IL-6 12 weeks [71] 
Fetal Liver Unknown SCF 35 days [63] 
Embryonic 
Stem Cells 
CD34+CD43+ 
cell 
SCF, IL-3, IL-6, Flt-3 
ligand 
10-14 
weeks 
[65] 
 
 
While the exact regimen used to differentiate these cells into MCs depends on the 
study and are reviewed in Table 2.2, most make use of recombinant cytokines such as 
IL-3, IL-6 and SCF. Differentiation protocols generally take multiple months to complete 
and often require several different differentiating molecules administered at intervals. 
These protocols can allow production of MCs in numbers sufficient for laboratory 
studies. It is unclear to what extent these cells recapitulate the phenotype of either skin or 
mucosal MCs, however it seems clear that they are preferable to the use of rodent MCs or 
transformed human MC lines.  
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II.4 Human Mast Cell Lines 
II.4.i HMC1/2 
 The human MC (HMC-1) line was created in 1988 at the Mayo Clinic from cells 
taken from the peripheral blood of a patient with “mast cell leukemia” [72] and 
constitutes the first human MC line. Since its creation, the HMC-1 cell line has 
contributed to countless discoveries, with the initial paper describing it bearing well over 
five hundred citations. These MCs were found to be most similar to immature MCs in 
that they did not contain significant levels of histamine nor did they express FceRI, 
however they did express the receptor for stem cell factor c-KIT, albeit a mutated version 
of it. It was determined using sequencing and site directed mutagenesis that HMC-1 
carried an allele of the c-kit gene that carried a missense mutation that changed an 
aspartic acid residue to a valine. This substitution in turn created a constitutively active 
receptor that lead to the hyperplasia observed in the original donor and conveyed the 
HMC-1 cell line to continue to proliferate in culture [73]. These cells were found to 
express the major histocompatibility complex class II antigen molecules HLA-DR, HLA-
DQ and HLA-DP, of which HLA-DR and HLA-DQ were found to be inducible by 
recombinant human interferon gamma (rhIFN-g) and recombinant human IL-4 (rhIL-4) 
[74]. Further investigation revealed that HMC-1 expressed functional b-tryptase as 
opposed to a-tryptase, and interestingly, while HMC-1 lacked the alpha and beta chains 
of the FceR, they showed strong expression of the gamma chain (which is shared by the 
Fcg receptor) [75]. One of the greatest utilities of the HMC-1 cell line was and indeed 
continues to be, in the study of MC leukemia, or what we now refer to as mastocytosis, 
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which is very often the result of similar activating mutations in c-kit. However as useful 
as it may have been, it also has many obvious drawbacks including its lack of FceRI 
expression, lack of histamine, mutant form of c-kit and inability to degranulate in 
response to appropriate stimuli.       
 
II.4.ii LAD2 
 Citing the problems mentioned above with the HMC-1 human MC line, 
researchers at the Laboratory of Allergic Diseases (LAD) at the NIH in 2002 established 
and characterized a second human MC line LAD2 [76]. These cells were taken from the 
bone marrow of a patient also suffering from mastocytosis. From this donor, five cell 
lines were reportedly created, LAD 1-5, however only LAD1 and LAD2 were reported 
on in the initial publication of these findings and of those, LAD2 is the most widely used 
today. Cells grown from the initial bone marrow sample were cultured for 24 months 
before being designated as official cell lines.  Following this period of culture, the cells 
were cryogenically stored and reconstituted, after which point various phenotypic and 
functional tests were performed to determine the degree to which these cells resembled 
mature MC isolated from human tissue. LAD cells were found to be roughly 98% 
tryptase positive and 37% tryptase/chymase positive and contain between three and six 
times as much histamine as HMC-1. Degranulation could be induced by IgE mediated 
FceRI aggregation and FcgR upregulation could be achieved using IFN-g. Importantly, 
unlike HMC-1 cells, LAD cells were found to possess the wild type allele of c-kit and 
thus were dependent on the addition of SCF to their growth media in order to proliferate. 
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While LAD2 cells do not carry the activating mutation in c-kit and are dependent on SCF, 
they are transformed, leukemic cells and therefore cannot be considered normal human 
MCs. In the years since the establishment of the LAD2 cell line it has been described as 
having exceedingly low levels of tryptase and chymase [12][77] as well as unacceptably 
large variability in terms of basic characteristics like doubling time and response to 
cryopreservation [78]. While there are significant limitations concerning the use of LAD2 
cells, the creators of this cell line continue to tout their utility [79], citing a somewhat 
steady rate of materials transfer agreements and licensing agreements being entered into 
in the years since their establishment.   
 
II.4.iii LUVA 
 The final human MC line was developed at the University of Virginia in 2011 and 
are called LUVA (named after Dr. Larry Borish at UVA who first described them). They 
were reported to arise from a population of CD34+ cells taken from the peripheral blood 
of a patient who appeared healthy with respect to mastocytosis but was suffering from 
aspirin-exacerbated respiratory disease. Similar to LAD2 cells, LUVA cells did not carry 
a mutated form of c-kit, however in stark contrast to LAD2 cells could be cultured in the 
absence of SCF. This result in combination with the lack of any detectable mastocytosis 
in the original donor, remains perplexing and unexplained and is worthy of further 
investigation. Phenotypically LUVA cells were found to express c-KIT, FceRI, FcgRII, 
tryptase and chymase. They were reported to degranulate in response to IgE-mediated 
FceRI aggregation as determined by release of b-hexosaminidase, thromboxane A2 and 
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prostaglandin D2 [78]. In the seven years since they were first described, a modest 
amount of work has been done with LUVA cells and they may well constitute the closest 
approximation of any currently available immortalized cell line of a normal human MC. 
One major impediment to their use is the aforementioned question of the mechanism of 
their immortalization that will need to be resolved. 
 
II.5 Animal Models of MCs 
II.5.i Mouse Models 
 The first mouse model used in the study of MC biology was a line that carried a 
mutation in the white locus. These mouse among several other hematopoietic 
deficiencies, showed an almost complete lack of MCs [80]. The white locus has since 
been found to be the location of the gene for the stem cell factor receptor c-KIT. The 
W/W-v mouse line, as it was named, carried two copies of a non-functional c-kit. Seminal 
bone marrow transplant experiments were performed with these mice demonstrating the 
bone marrow origin of the MC precursor. This mouse model has been a workhorse of the 
MC biology field; however, its utility may be approaching its end as we learn more about 
it. Disregarding for now the significant differences between murine and human MC 
biology, the W/W-v mouse model is problematic because the MC development is far from 
the only process controlled by c-kit. Indeed c-kit plays a role in many hematopoietic 
processes, and therefore attributing observations seen in these mice solely to the lack of 
MCs simply cannot be done [81].   
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II.5.ii Caveats with Murine Mast Cell Biology 
 The most well characterized animal models of MCs come from rodents. This is 
peculiar in a sense as rodent and human MC biology is very divergent, indeed much more 
so than would be expected given the close phylogenetic positions of humans and rodents 
and certainly more than would be expected given the power rodent models have had in 
the past when providing models for human biology. There are many reasons for this 
including the fact that human IgE does not bind to mouse FceRI, the fact that MCs in 
rodents arise from both the bone marrow and spleen, whereas MC in humans are thought 
to arise only from the bone marrow.  
 
II.6 Adipose Derived Stem Cells (ADSCs) 
 The initial description of adipose derived stem cells (ADSCs) was in 2001 in a 
landmark paper that has since been cited over 4,500 times [82]. The motivation of this 
work was to provide an accessible source of autologous adult stem cells. At the time this 
work was done the most common source of adult stem cells was bone marrow 
mesenchyme [83]. Bone marrow contains two types of stem cells, hematopoietic stem 
cells that give rise to all the cells in the blood and mesenchymal stem cells which are 
found in the mesenchymal stroma and which give rise to bone, fat, cartilaginous [84] and 
muscle tissue producing cells [85]. While useful to the field of tissue engineering, the 
highly invasive nature of bone marrow collection and the low numbers of cells obtained 
in this way drove the authors to search for an alternative. It was understood at the time, 
based on studies in animals of various vertebrate groups including rodents [86], birds [87] 
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and rabbits [82], that connective tissue found in and around organs contained 
mesenchymal stem cells, similar in differentiability to the mesenchymal stem cells 
obtained from bone marrow. Adipose tissue was chosen as a potential source of 
mesenchymal stem cells as contains a significant amount of connective tissue, but more 
importantly because adipose tissue, like the bone marrow is formed from the embryonic 
mesoderm and therefore it was postulated that stem cells derived from it should have 
similar lineage commitments [88].  
 
II.7 Stromal Vascular Fraction (SVF) 
Adipose tissue is a complex mixture of cells, but can be separated experimentally 
into two fractions, adipocytes in one and all remaining cells in another. The non-
adipocyte fraction is termed the Stromal-vascular fraction (SVF) and has been recognized 
and utilized since 1964 when collagenase digestion was used to liberate adipocytes from 
rat adipose tissue [89]. Since its establishment in 1964, the SVF has been used in the 
study of adipocyte biology [90]–[92].  
 
II.8 ADSC Isolation 
When the isolation of human ADSCs was first performed, SVF cells were isolated 
from human liposuction aspirate by digestion with 0.075% collagenase followed by 
centrifugal fractioning. SVF cells were plated and allowed to adhere overnight, the cells 
remaining after a media change to remove non-adherent cells were termed processed 
lipoaspirate (PLA) cells. PLA cells were cultured in DMEM supplemented with 10% 
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FBS, 1% Antibiotic/Antimycotic. PLA cells were subjected to multiple forms of 
interrogation including flow cytometry, immunofluorescent staining, determination of 
doubling time and senescence, and differentiation capacity [82]. While various minor 
changes have been made to this protocol, much of the process has remained unchanged. 
Some of the improvements and alternative methods are discussed in more detail. 
 
II.8.i Source of Adipose Tissue 
 The composition of adipose tissue is dependent on which part of the human body 
it is collected from and the properties of the cells collected depend on the manner in 
which it was removed. The two forms of human adipose tissue that are commonly 
available to researchers are bulk adipose tissue removed during surgery and the aspirate 
collected during liposuction procedures. While surgically removed adipose tissue may 
come from many parts of the body, it is generally subcutaneous adipose tissue collected 
from the breast, abdomen or lower extremities (Personal Observation). Omental adipose 
tissue may also be used as a source of ADSCs [93], however due to the invasive nature of 
its collection, is not an ideal candidate as a source of autologous stem cells for therapies. 
Liposuction aspirate is almost exclusively abdominal (Personal Observation) and it has 
been shown that stem cells can be isolated from one of two fractions [94], that are 
analogous to polar and non-polar phases in a mixture of two immiscible liquids. A 
comparison was performed on of the characteristics of ADSCs taken from the abdomen 
or the waist (hip or thigh) [95]. This study demonstrated that the differentiative capacity 
of cells taken from these two sites were similar, with no statistically significant difference 
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observed in osteogenic or chondrogenic differentiative capacity. A difference was 
observed in the number of differentiatable cells, with the abdominal tissue yielding 
roughly five times as many cells as tissue taken from the waist. In a study of ADSCs in 
mice it was found that significant differences were observed in the characteristics of stem 
cells derived from fat pads in different organs [96], classed in the study as either visceral 
or subcutaneous adipose tissue. Another comparative study was performed to determine 
the effect of adipose tissue collection method on the characteristics of the stem cells 
yielded [97]. In this study, cells derived from either bulk tissue or liposuction aspirate 
collected using a power assisted or laser assisted technique were investigated for their 
proliferative and differentiable qualities, with the laser assisted liposuction yielding the 
lowest quality stem cells.  
 
II.8.ii Isolation Technique 
In addition to differences stemming from the location of the adipose tissue 
collected, at least three different techniques for isolation have been developed. The first 
alternative method is the explant or bulk tissue culture method, which is performed by 
simply placing adipose tissue in cell culture media and allowing the ADSCs to exfiltrate 
the tissue [98][99]. While these methods are attractive given the ease and low number of 
consumables used, these methods are significantly less efficient and are likely to yield a 
population of cells enriched in motile cells that may or may not be useful for subsequent 
therapies. The second alternative method for the isolation of ADSCs is the use of 
enzyme-free, mechanical isolation protocols designed with human therapies in mind that 
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make use of hydrodynamic shear forces to disrupt intact tissue within liposuction aspirate 
[100]. These procedures yield what is known as “Nanofat” and is performed by serially 
passing liposuction aspirate back and forth between two luer-locked syringes. This 
method was developed and popularized by cosmetic surgeons for whom the use of 
emulsified adipose tissue is beneficial for various processes in cosmetic surgery [101]–
[103]. This technique is attractive for the same reasons as the explant culture method, 
however its success depends on the nature of the tissue being used, with bulk tissue being 
unsuitable and certain liposuction aspirates also being unsuitable depending on the bore 
of the canula used during the liposuction procedure (Personal Observation). The third 
type of isolation techniques makes use membranes to separate the ADSCs from the other 
cell types found in the SVF. The simplest of the membrane-based techniques is the 
membrane filtration technique [104], in which the enzymatically dispersed SVF is passed 
through a single membrane of polyurethane with an average pore size of 11 µm. Due to 
the low purity of the cultures obtained in this way, the membrane filtration procedure was 
then further modified to include an intermediate incubation step wherein the membrane 
used for filtration is incubated in a tissue culture dish to allow cells bound to the 
membrane to detach and migrate onto the surface of the plate [105]. This additional step 
reportedly improved both the extent of mesenchymal stem cell markers as well as the 
ability of these cells to differentiate into osteoblasts [106].  
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II.9 Differentiative Capacity of ADSCs 
 As previously discussed, adipose tissue is derived from the embryonic mesoderm 
and ADSCs are most commonly differentiated into muscle, bone, fat and cartilage as 
summarized in Table 2.3, although the differentiation of these cells into other cell types 
has also been reported, including cardiomyocytes [107], neurons [108] and endothelial 
cells [109] as summarized in Table 2.4. 
 
Table 2.3. Differentiation Protocols for Adipogenic, Chondrogenic, Osteogenic and 
Myogenic Differentiation of ADSCs. Summarized are the four most common cell 
types produced by differentiation of ADSCs. 
 
Cell Type Morphogen Duration Reference 
Adipocyte Isobutyl-methylxanthine, 
dexamethasone, insulin, 
indomethacin 
2 weeks [82] 
Chondrocyte Insulin, TGF-b1, ascorbate-2-
phosphate 
2 weeks [82] 
Osteoblast Dexamethasone, ascorbate-2-
phosphate, b-glycerophosphate 
2 weeks [82] 
Myocyte Dexamethasone, hydrocortisone 6 weeks [82] 
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Table 2.4. Differentiation Protocols for Cardiomyogenic, Neurogenic, Epithelial and 
Endothelial Cell Differentiation of ADSCs. 
 
Cell Type Morphogen Duration Yield Purity Reference 
Epithelial Cell All-trans 
retinoic acid 
10 days NA ~80% [110] 
Endothelial 
Cell 
Hydrocortisone, 
vitamin c, 
heparin, EGF, 
FGF2, IGF-1, 
VEGF 
6-10 days NA NA [111] 
Neuron Butylated 
hydroxyanisole, 
KCl, valproic 
acid, forskolin, 
hydrocortisone, 
insulin 
>24 
Hours 
NA NA [112] 
Cardiomyocyte 5-azacytidine or 
trichostatin A 
3 weeks NA NA [113] 
 
 
II.10 ADSC Phenotype  
II.10.i Morphology 
 Morphologically, ADSCs in culture appear indistinguishable from fibroblasts. 
They are characterized by their long, spindle-shaped appearance and their propensity to 
adhere to tissue culture plastic. ADSCs grown in culture grow and divide rapidly and 
exhibit contact inhibition. Considerable variation is observed in proliferation and 
heterogeneity of morphology in cell preparations produced from different donors 
(Personal Observation). 
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II.10.ii Immunophenotype 
 Considerable debate exists in the field of ADSC biology about the exact 
immunophenotype of the ADSC. This discrepancy is almost certainly the product of the 
varied protocols used for isolation of ADSCs as well as the highly heterogeneous nature 
of the SVF. While certain CD markers are widely agreed upon throughout the field as 
either positive or negative markers of ADSCs, others appear as positive markers in some 
studies and negative markers in others. Resolution of these disputes will be necessary as 
human therapies are designed using ADSCs. A meta-analysis of 16 publications from 
2002 to 2016 ([94], [114]–[128]) showed that out of 48 cell surface markers, 15 were 
unanimously reported as positive (Table 2.5), 18 negative (Table 2.6) and 15 were 
reported as both positive and negative markers in two or more reports (Table 2.7). 
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Table 2.5. Undisputed Positive ADSC Markers. Out of sixteen publications 
describing positive markers of ADSCs, all agree upon the identity of these markers 
as positive.  
 
Undisputed 
Positive Markers 
Number of 
Reports 
CD9 4 
CD10 3 
CD13 4 
CD29 6 
CD36 1 
CD44 7 
CD49e 2 
CD51 1 
CD55 4 
CD59 4 
CD90 15 
CD117 2 
CD133 1 
CD142 1 
HLA-ABC 3 
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Table 2.6. Undisputed Negative ADSC Markers. Out of sixteen publications 
describing negative markers of ADSCs, all agree upon the identity of these markers 
as negative. 
 
Undisputed 
Negative Markers 
Number of 
Reports 
CD3 1 
CD11 1 
CD11a 1 
CD11b 3 
CD11c 1 
CD14 6 
CD16 3 
CD18 3 
CD19  1 
CD20 1 
CD31 8 
CD35 1 
CD45 13 
CD50 3 
CD56 4 
CD62 2 
CD73b 1 
CD104 3 
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Table 2.7. Disputed ADSC Markers. Out of sixteen publications describing either 
positive or negative markers of ADSCs, the CD molecules in this table appeared at 
least once as both positive and negative markers of ADSC identity. 
 
Debated 
Markers 
Number of 
Reports Positive 
Number 
of Reports 
Negative 
CD34 9 7 
CD49b 1 1 
CD49d 5 1 
CD54 4 1 
CD61 1 2 
CD62e 1 2 
CD63 1 1 
CD71 4 1 
CD73 9 1 
CD105 13 2 
CD106 3 4 
CD140a 1 1 
CD146 4 3 
CD166 4 1 
HLA-DR 1 4 
 
 
II.11 Breast Cancer  
 Breast cancer is the most common form of cancer in women regardless of age, 
race or ethnicity. Furthermore, with the exception of prostate cancer in certain ethnic 
groups, breast was the most common site of all cancers in the United States between 2010 
and 2014. According to the Centers for Disease Control and Prevention statistics, roughly 
236,000 women were diagnosed with breast cancer in 2014, and roughly 41,000 women 
lost their lives as a result of having the disease. According to the same study, the rate of 
 
37 
incidence among women of all races was 123.9 per 100,000 women, higher than for any 
other site in the body [129].  
 
 
Figure 2.2. Rates of Cancer Among Americans Between 2010 and 2014. Centers for 
Disease Control and Prevention statistics showing the ten most common locations of 
cancer among Americans over a four year period showing breast to have the highest 
prevalence [129]. 
 
 
 Breast cancer is a highly heterogeneous disease which exhibits varying degrees of 
severity, morphology, mutational burden and mechanism of progression. One method of 
classification of breast cancer is through the expression of certain compliments of genes 
[130]. Using this system of classification breast cancers can be first grouped by their 
expression of the estrogen receptor (ER) and thereafter by the duplication [131] and 
overexpression of the oncogene Erb-B2, which was found to be expressed in up to 30% 
of all breast cancers [132]. While this system of classification was useful, it has since 
been improved upon, in particular with the recognition of the role played by the 
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progesterone receptor (PR). Much of the early work and many of the early therapies 
targeted one or more of these three proteins with a high degree of success. In at least 12% 
of female breast cancer patients the expression of all three of these genes are ablated and 
their tumors are therefore refractory to steroid hormone treatment and any therapy 
targeting the Erb-B2 gene product, HER2, these tumors are termed triple negative [133]. 
 
II.11.i HER2 in Breast Cancer 
 HER2 is a member of the epidermal growth factor receptor (also known as ERBB 
[134] and HER) family [135], which are transmembrane tyrosine kinase receptors. This 
family is composed of four members, namely HER2-4 (also known as ERBB2-4) and the 
epidermal growth factor receptor or EGFR (also known as ERBB1). As with other 
receptor tyrosine kinase proteins, binding of the cognate ligand to the extracellular 
domain induces dimerization with other ERBB receptors forming either homodimers or 
heterodimers. Ligand binding and dimerization induce conformational changes and 
interactions that lead to phosphorylation of tyrosine residues within the cytoplasmic 
domains of the two receptors. The phosphorylated tyrosine residues in the cytoplasmic 
domains create binding sites for other cytoplasmic signaling molecules that are able to 
activate or inhibit signaling pathways in a variety of ways. Activated ERBB family 
receptors predominantly signal through the mitogen-activated protein kinase (MAPK) 
pathway or the phosphatidylinositol 3 kinase (PI3K) pathway, however they also interact 
with and signal through members of the STAT family, the tyrosine kinase SCR and the 
master regulator mammalian target of rapamycin (mTOR). 
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Ligands for these receptors include epidermal growth factor family ligands summarized 
in Table 2.8 [136].  
 
Table 2.8. Ligands for the Four ERBB Family Receptors. Ligands for the ERBB 
family receptors are grouped according to their shared or unique binding to 
different isoforms [136]. 
 
Receptor Specific Ligands Shared Ligands 
EGFR EGF, transforming growth 
factor a, amphilregulin 
Betacellulin, heparin 
binding EGF, 
epiregulin 
HER2 None None 
HER3 None Neuregulin 1, 
Neuregulin 2 
HER4 Neuregulin 3, neuregulin 4 Betacellulin, heparin 
binding EGF, 
epiregulin, Neuregulin 
1, Neuregulin 2 
 
 
 Although HER2 does not have a soluble cognate ligand, it does have a membrane 
associated ligand MUC4, the binding of which leads to the phosphorylation of at least 
one tyrosine residue, Tyr-1248, which is creates a binding site for the protein downstream 
of kinase related (DOK-R) [136] and may play a role in receptor localization of HER2 
[137]. Despite the fact that HER2 does not bind any of the ligands bound by other ERBB 
family members, it nevertheless plays an important role in modulating the activity of 
other ERBB family receptors through ligand induced dimeric interactions with other 
receptors. Indeed, HER2 has been shown to be the preferred heterodimeric binding 
partner of ligand-bound ERBB receptors [138].  
 In the context of cancer biology, ERBB family receptors play an important role, 
indeed EGFR has been recognized for its role in the progression of cancer for over three 
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decades [139]. ERBB family receptor activity is typically found to be irregularly high in 
cancer cells, with this increase in activity arising by various mechanisms. In certain 
instances, the number of receptors is increased due to increases in gene copy number, 
with duplications of the genes important events of the progression of cancer 
development. The most commonly duplicated genes in the Erb-b family are EGFR [140] 
and HER2 [141]. In other instances, where the gene copy number and receptor number 
are not increased, paracrine and autocrine signaling stimulate receptor activity [142]. 
Activation of ERBB family receptors through any of the aforementioned mechanisms 
lead to increased cell proliferation as well as production of angiogenic signals such as 
vascular endothelial growth factor (VEGF) [143].  
 
II.11.ii The Role of MC in Cancer 
MCs are most commonly associated with their role in Type I hypersensitivity 
[144], however given their ubiquitous distribution in tissue, their role in all forms of 
cancer has been studied extensively [3][145][146]. MC are the first immune cells to 
localize to tumors and to enter the tumor microenvironment, yet their contribution to 
tumor progression and metastasis is highly tumor-specific and widely debated [147]. It 
has, for example been shown in some animal models that MC can have pro-tumorigenic 
effects, while in other models or even in some cases in the same tumor, MC seem to have 
an anti-tumorigenic effect. These seemingly conflicting results may be the result of 
differences in the subtype, stage, or grade of the tumors investigated or the various 
methods used to identify MCs. Furthermore, differences in rodent and human MC 
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biology are many and therefore the results obtained using these models do not accurately 
reflect the corresponding human disease state and can ultimately lead to misleading 
conclusions [148], [149][150]. There is clearly a great deal that remains unknown about 
the role of MC in cancer and many important questions remain unanswered.  
Despite these outstanding questions, it is also clear that in at least certain human 
cancers, namely breast and colo-rectal cancers, the presence of MC in particular parts of 
the tumor can be associated with a favorable survival outcome [8][151][152][4]. As 
previously discussed, one of the components of MC granules is TNF-a, indeed they are 
one of the only cell types in humans that have pre-formed TNF-a that can be released 
upon activation of FceRI [153][154]. In addition to TNF-a, MC can synthesize and 
release large amounts of granulocyte-macrophage colony-stimulating factor (GM-CSF), 
up to 4 ng/mL from 100,000 cells [155][156], reactive oxygen species, prostaglandin D2, 
IL-9 and heparin [3], many of which have potential anti-tumorigenic effects. The effect 
of the various molecules released from MC in the breast cancer tumor microenvironment 
remains to be determined. 
 
II.11.iii The MC Cytokines TNF-a and GM-CSF as Anti-Cancer Agents 
 Tumor necrosis factor a was first described in the 1970s [156][157] and has since 
been shown to be a cytokine that is highly multifunctional and consequently it plays roles 
in multiple parts of human physiology, such as regulating vascular tone through its 
interaction with vascular endothelial and smooth muscle cells. TNF-a also, as its name 
might suggest, has the ability to inhibit tumor cell proliferation and in certain cases 
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promote tumor regression. TNF-a can also function in the form of an adjuvant, 
increasing the efficacy of chemotherapeutic drugs such as doxorubicin or a EGFR 
tyrosine kinase inhibitor [158]. The most significant drawback when considering TNF-a 
as an anti-cancer drug is its toxicity when administered systemically, leading to the 
investigation of its utility in the treatment of tumors in which local administration is 
contained by the surrounding organ. One method of administering TNF-a that has shown 
some success has been through isolated limb perfusion of TNF-a [159] in combination 
with drugs such as melphalan [160][161], or doxorubicin [162] introduced under 
hyperthermic conditions [163].  
 GM-CSF is another cytokine produced by MC that is being examined for its 
potential utility as either a treatment [164], or an addition to immunotherapeutic 
approaches to treating breast cancer such as trastuzumab IgG [165] or docetaxel [166]. 
One such approach uses the immunogenic peptide E75 in conjunction with GM-CSF to 
treat tumors in breast cancer patients. Using this approach, there was an observed 
reduction of 48% in the relative risk of recurrence when E75 was administered with GM-
CSF as compared to E75 alone, a finding that paved the way for a Phase III clinical trial 
of this combination [167].  In another study of individuals with metastatic trastuzumab-
resistant HER2 positive breast cancer, GM-CSF co-administration with trastuzumab was 
shown to have increased therapeutic effect as compared to trastuzumab alone [165]. In 
addition to these studies, more than 50 clinical trials are either complete or in progress 
which examine the potential benefits of GM-CSF in cancer treatment, providing 
encouraging evidence for its use in cancer therapies. 
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II.12 Allergo-Oncology 
 The association between allergy and cancer has been the topic of investigation 
since at least 1955, when a study was done to examine the effect of an allergic 
inflammatory response to tumor grafts in mice [168]. This investigation did not show any 
effect of allergic response on tumor progression, however research continued into 
possible connections between allergy and cancer. In 1976 an association study was done 
to compare the prevalence of atopy in cancer patients which reported that atopy was 
found at rate fifteen folds less than in non-cancer bearing individuals [169].  In the 1980’s 
studies were done that showed that histamine levels in patients with tumors were 
decreased compared to a control group and that upon removal of the tumor load, the 
patients histamine levels returned to normal levels [170]. Similar results were obtained 
when response to histamine was measured in the skin of cancer-bearing versus non-
cancer bearing individuals, where patients with tumors or having recently had tumors 
removed showed a diminished ability to respond to sub-dermal injections of histamine 
[171]. Initially, the decreased level of histamine in cancer patients was attributed to the 
observation that these patients had lower numbers of circulating basophils in their blood 
as compared to non-cancer bearing control patients [172]. Basophils isolated from the 
tumor bearing population were found to be normal with regards to histamine content and 
ability to degranulate. It is interesting to note that MCs were not examined in this study, 
however it may not have been feasible to obtain MCs from patients to perform the study. 
In 2005 a study of over one million participants was performed to determine the 
association between risk of mortality from cancer and hay fever/asthma which found a 
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decreased risk of mortality from cancer in individuals who reported that they had either 
hay fever or asthma [173]. Given these reported associations between cancer and allergy 
and given the growing desire to engage the immune response in destroying tumors in 
cancer patients, the question of whether the allergic response could be used in destroying 
tumors began to be asked [174] and the field of allergo-oncology was born. The term 
“allergo-oncology” seems to have originated or at least became popularized around the 
year 2008 [175] and refers to the use of the allergic hypersensitivity reaction to fight 
cancer. Of particular interest to the nascent field of allegro-oncology was the IgE 
molecule, the immunoglobin most commonly associated with hypersensitivity and the 
allergic arm of the immune system in general. The IgE molecule and its receptor have 
many attractive properties from the point of view of therapy development that in some 
cases may make it a more sensible platform than IgG. The first and perhaps most obvious 
advantage of IgE is its affinity for its receptor. The interaction of IgE with the FceRI 
receptor is orders of magnitude higher than that of IgG for its receptor. This very high 
affinity of IgE for its receptor means that upon receptor binding, IgE molecules tend to 
stay bound to their receptors and are therefore able to decorate effector cells for longer 
periods, reportedly for up to several months, or certainly for the lifetime of the cell to 
which they are bound [175]. In part due to the high affinity for the FceRI receptor and its 
resultant sequestration, IgE levels in the blood tend to be kept very low [176]. In mice it 
was shown that IgG subtypes had serum half-lives of between 4 and 8 days, whereas IgE 
had a half-life of only 12 hours [177]. While these timescales are likely to be slightly 
different in humans, they are nonetheless a good illustration of the stark difference in 
 
45 
serum persistence among the different immunoglobin classes. The advantage of the short 
half-life of IgE is that it minimizes the risk of exogenously administered antibodies to 
induce systemic anaphylaxis, a major possible complication for any antibody-based 
therapy. In addition to its short half-life, the concentration of IgE is also kept very low, 
with IgE making up only 0.02% of the total complement of Ig’s in the blood, IgG on the 
other hand, accounts for up to 85% of the total Ig complement [175]. This may serve to 
create less competition for free receptors for IgE as compared to IgG where the majority 
of receptor sites are likely to be occupied.       
 
II.12.i MOv18 
One of the first reported uses of allergo-oncology came in 1999 [178] when an 
IgE recognizing the folate receptor was created and assessed for its ability to kill ovarian 
cancer cells. In this study, MOv18-IgG1, a previously characterized IgG1 specific to the 
folate receptor, was used. MOv18-IgG1 had been shown previously to be capable of 
inducing antibody-dependent cell-mediated cytotoxicity (ADCC) of an ovarian cancer 
cell line by peripheral blood mononuclear cells [179]. In order to start to understand the 
effect of Ig subtype, a chimeric antibody was created that fused the Fc domain of IgE to 
the variable domain of MOv18-IgG1. The resultant antibody was compared to the 
original IgG1 for its ability to induce ADCC. 
The choice to target the folate receptor and ovarian cells was based several factors 
including the previous observation that ovarian cancer was less prevalent in individuals 
with high levels of allergic activity [173], the high degree of fatality associated with this 
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disease and the existence of previously validated models of IgG1-mediated tumor cell 
cytotoxicity, namely the cell line IGROV1 and the MOv18-IgG1 antibody. It was 
determined in a direct comparison between the two antibodies, MOv18-IgE and MOv18-
IgG1 that the IgE-based antibody induced significantly more tumor cytotoxicity than did 
the IgG1-based antibody and did so for a longer duration in a severe combined immune-
deficient (SCID) mouse xenograft model of ovarian cancer. The same group of 
researchers followed this study with an investigation of the same MOv18-IgE in a nude 
mouse model [180]. In this study, human ovarian cell tumor tumors were induced in nude 
mouse in conjunction with human peripheral blood-derived monocytes. Using this model 
system investigation of the contribution of IgE-mediated monocytic tumor cytotoxicity 
was possible due to the fact that human IgE does not bind mouse FceRI. The authors 
reported that MOv18-IgE was able to induce ADCC both in vivo and in vitro. In the in 
vivo experiments, where injection of human monocytes and MOv18-IgE resulted in 
tumor infiltration by monocytes and was able to increase survival in tumor bearing mice 
to a higher degree than MOv18-IgG1. In the in vitro studies, MOv18-IgE was able to 
induce ADCC and facilitated phagocytosis of cancer cells by IgE-bearing monocytes, a 
process termed antibody-dependent phagocytosis (ADCP). Following on from this work, 
an investigation into  the mechanism of IgE-mediated ADCC was undertaken [181], 
namely the differentiation between ADCC and ADCP and to determine to what extent the 
two FceR’s are involved in these processes. Using a sophisticated, three color flow 
cytometry assay, the authors were able to show that the high affinity IgE receptor FceRI 
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mediated ADCC of cancer cells by human monocytes, whereas the low affinity IgE 
receptor CD23 meditated ADCP.       
 
II.12.ii HER2 
 After the success of MOv18 and the targeting of the folate receptor to induce 
cancer cell targeting and killing, other targets were investigated, perhaps the most 
promising of which was the protein HER2.  HER2 was chosen in part due to the 
existence of an IgG molecule targeting HER2, trastuzumab and the success it had shown 
as the antibody-based therapy Herceptin. The first development of IgE molecules 
targeting HER2 was achieved using an oral-administration based vaccination of mice 
with peptides engineered to mimic the epitope of HER2, or “mimotopes”, bound by 
trastuzumab [182][183]. Using this strategy, HER2 antibodies produced by mice were 
able to induce tumor cell killing when incubated with a rat basophil cell line. In light of 
these successes with targeting HER2 on cancer cells and the success of the work 
performed to create and employ a humanized IgE-IgG chimeric antibody, Trastuzumab-
IgE was created and characterized [184]. The resultant antibody was found to be capable 
of ADCC and was able to induce degranulation of MCs when incubated with HER2 
positive cancer cells. A comparison of trastuzumab-IgE showed comparable cytotoxic 
effects to trastuzumab, however the trastuzumab-IgE mediated ADCC, whereas 
Trastuzumab mediated ADCP. The trastuzumab-IgE antibody is a humanized antibody, 
but is not fully human, for this reason a fully human IgE targeting HER2 was created 
[185]. The antibody, designated as C6MH3-B1, was able to induce degranulation of 
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basophils when co-incubated with HER2 positive cancer cells, similar to the previously 
examined antibodies. C6MH3-B1 was also shown to play a role in antigen presentation 
by human dendritic cells in vitro. The authors also investigated the ability of the soluble, 
extra-cellular domain of HER2 (ECDHER2) to induce degranulation of basophils decorated 
with C6MH3-B1, which it did not. This was an important piece of information as HER2 
is known to shed part of its extracellular domain into a soluble form that can be detected 
in the bloodstream. In the event that soluble ECDHER2 was able to induce degranulation, 
the introduction of HER2 IgE could cause systemic anaphylaxis when MCs, basophils 
and other effector cells decorated with the antibody encountered the soluble antigen. To 
further ensure that systemic anaphylaxis would not be likely in a human application, an in 
vivo mouse model was employed. Using this model, it was shown that ECDHER2 was not 
able to induce local anaphylaxis. In the mouse model used, the endogenous gene for the 
alpha subunit of FceRI was removed and replaced with the human sequence of FceRIa to 
allow binding of the human IgE to mouse effector cells. It should be noted that while 
MCs and basophils in this model are able to bind the human IgE via the FceRI receptor, 
other effector cells that interact with IgE via the low affinity CD23 receptor are not able 
to bind IgE, thus limiting the predictive ability of this model. Despite its possible 
limitations, the authors were able to show that administration of C6MH3-B1 was able to 
prolong the lifespan of mice bearing HER2 positive human breast cancer cells as 
compared to control IgE. Finally, a very small study was performed in the non-human 
primate model system Macaca fascicularis, with two monkeys being injected with either 
low or high concentrations of C6MH3-B1 and subsequently monitored for overall health 
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and eating habits and the serum concentrations of human IgE were measured after one 
week. The animals in the study displayed no adverse effects of treatment and human IgE 
levels returned to normal by the one-week observation point. While this study was very 
limited and would need to be expanded upon before conclusive statements can be made 
about the safety of C6MH3-B1, it is nevertheless encouraging.  
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CHAPTER III 
DIFFERENTIATION OF MAST CELLS FROM ADIPOSE DERIVED STEM 
CELLS 
 
III.1 Introduction 
Adipose Derived Stem Cells (ADSCs) were first identified in 2001 as 
mesenchymal-type adult stem cells present in the stromal vascular fraction (SVF) of 
human liposuction aspirate [82]. Their presence was hypothesized due to the previous 
observation of mesenchymal stem cells in connective tissues of other vertebrate groups as 
well the fact that adipose tissue is derived from the same embryonic tissue (mesoderm) as 
bone marrow, the previous source of autologous adult stem cells. The aim of the study in 
which ADSCs were initially described was to develop an alternative source of autologous 
stem cells for tissue engineering given the highly invasive and painful nature of bone 
marrow extraction. The common wisdom at the time of their discovery was that the 
differentiative capacity of ADSCs were limited to the classical four normally associated 
with mesenchymal stem cells, namely adipogenic, osteogenic, chondrogenic and 
myogenic. In the years since the identification of ADSCs, researchers have successfully 
differentiated them into cell types of both endodermal and ectodermal origin. MCs are a 
difficult cell type to study in the laboratory setting; the reasons for this are twofold. The 
first reason is that they are difficult to obtain in large numbers from human donors. MCs 
are most commonly isolated from skin removed during surgical procedures. This process
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is costly and inefficient, and the resultant cells take months to grow to a number 
sufficient to perform experiments. The second contributing factor to the difficulty of the 
study of MC biology in humans is the significant difference that exists between human 
and murine MC biology [149], [150]. The fundamental requirement for a model system is 
that it faithfully recapitulates the functions and phenomena one wishes to investigate, a 
requirement that is not satisfied by either mice or rats in regard to MCs and mechanisms 
underlying allergic disease. The difficulty posed by these two factors has limited the 
understanding of the role of MCs in both normal and diseased states of human 
physiology.  
 The purpose of this investigation was to test the hypothesis that ADSCs obtained 
from human adipose tissue could be used to differentiate into MCs as a new source to 
study MC biology. To this end we employed the SVF isolation method previously 
described and developed a protocol using morphogens produced by classically-derived 
human skin mast cells (hSMCs). The resultant cells were investigated using various 
metrics to confirm their identity as MCs. 
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III.2 Methods 
III.2.i ADSC Isolation 
 Adipose tissue was obtained in two forms, as bulk resected adipose (BA) tissue 
and as liposuction aspirate (LA). Liposuction aspirate was obtained locally from a plastic 
surgeon, whereas whole tissue was obtained from the Cooperative Human Tissue 
Network (UNCG IRB 12-0199). Adipose tissue was first washed in 1x Phosphate 
buffered saline with 1% penicillin/streptomycin and 1% amphotericin B to remove red 
blood cells. In the case of resections, tissue was homogenized mechanically using 
surgical shears to mince tissue and break up connective tissue. LA is mechanically 
homogenized during the liposuction procedure and therefore does not require as 
extensive mechanical homogenization or mincing as does BA. Thirty milliliter aliquots of 
homogenized tissue were placed in 50 mL tubes and digested in roughly 20 mL of 0.1% 
Collagenase Type IA in wash buffer (1x Hanks Buffered Salt Solution, 0.04% NaHCO3, 
1% FBS, 10 mM HEPES, 0.5% Amphotericin B, 1% penicillin/streptomycin) for 90 
minutes at 37°C under constant agitation. Following digestion, the dissociated cell slurry 
was filtered through sieves to remove undigested tissue then centrifuged at 360 x g for 15 
minutes to fractionate the slurry into a lipid-laden adipocyte layer, a turbid aqueous layer, 
and the cell pellet containing the SVF (Figure 3.1). The adipocyte rich phase and all but 
10 mL of the aqueous layer were removed and discarded. The remaining cell pellets were 
resuspended in fresh wash buffer and aliquots were pooled and centrifuged again at 360 x 
g for 10 minutes. The second centrifugation yields only a cell pellet and aqueous phase 
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which is removed and discarded. The remaining cell pellet is then plated in a tissue cell 
culture flask of varying size depending on the volume of tissue processed.  
 
 
Figure 3.1. Diagram of Fractionated Adipose Tissue. This figure shows the 
approximate proportions of each of the three phases produced by centrifugation of 
adipose cell slurry. The cell pellet contains the stromal-vascular fraction of adipose 
tissue. 
 
 
Cells were plated and grown for a minimum of one week in ADSC media 
(Dulbecco’s Modified Eagles Medium, 4.5g/L glucose, 10 mM HEPES, 10% FBS, 1% L-
glutamine, 1% penicillin/streptomycin/amphotericin B) at 37°C under a 5% CO2 
atmosphere. Media was changed once or twice per week and flasks were maintained in 
ADSC media until they reached confluence. Once cells reached confluence they were 
used for various applications including cryopreservation, characterization or 
differentiation into MCs as discussed below. ADSC cultures can be sub-cultured and 
expanded into a larger number of flasks, however this was not generally done as ADSC 
differentiative capacity is affected by passage number [118]. 
 
 
Lipid-Laden Adipocyte Layer 
Turbid Aqueous Layer 
Cell Pellet
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III.2.ii ADSC Characterization 
ADSCs were characterized using both transmitted and fluorescent light 
microscopy. Transmitted light microscopy was performed using an inverted microscope 
with phase contrast and collected using a CCD camera. For fluorescent microscopy, a 
Zeiss spinning disc confocal microscope was used to collect images. ADSCs were stained 
with MitoTrackerÔ Red CMXROS or MitoTrackerÔ Green FM for 30 mins, per the 
manufacturer’s instructions for time lapse experiments and were imaged unstained to 
analyze the autofluorescent properties of ADSCs.  
Immunophenotyping of cell surface receptors was performed using flow 
cytometry. Cells were first removed from flasks via incubation with CorningÔ 
CellStripper Dissociation Reagent at 37°C under a 5% CO2 atmosphere until cells 
released from the plastic. Cells were pelleted by centrifugation, washed with 1x Tris 
buffered saline (TBS) and resuspended in 1x TBS with 1:400 ratio of normal goat serum 
for 2 hours in order to block non-specific binding. Directly conjugated primary antibodies 
were purchased from BD Biosciences and used per manufacturers recommendations. The 
antibodies used and the conjugation of each is shown in Table 3.1. 
 
 
 
 
 
55 
Table 3.1. Antibodies Used for Flow Cytometry. The five antibodies listed above 
were used in the flow cytometric immunophenotyping of ADSCs. 
 
Marker Conjugation 
CD 105 FITC 
HLA-DR FITC 
HLA-ABC FITC 
CD 14 PE 
CD 44 PE 
 
 
Flow cytometry was performed using a FACSAriaÔIII flow cytometer equipped 
with a 70 µm nozzle. Detector voltages were set using unstained ADSCs as a negative 
control and the threshold was set automatically by the instrument software. At least 
100,000 events were recorded for analysis. 
 
III.2.iii Mast Cell Differentiation 
hSMC are grown in X-VivoÔ 15 media supplemented with 80 ng/mL of 
recombinant human stem cell factor (rhSCF). After a minimum of one week in culture, 
the media is removed from the hSMCs; this media is referred to as conditioned media. 
The conditioned media is then spiked with a 20 ng/mL human IgE, 20 ng/mL rhSCF and 
passed through a 0.22 µm filter to remove any cells that may have been inadvertently 
collected during the removal of media from the hSMC cultures. This filtrate is the final 
complete MC differentiation media. After culture of ADSCs in ADSC media for a 
minimum of one week, ADSCs were cultured in complete MC differentiation media for 
the remainder of the investigations. ADMCs could be collected a minimum of two weeks 
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after addition of differentiation media. Collection was often delayed a further two weeks 
to allow cultures to produce sufficient numbers of ADMCs for subsequent investigations. 
 
III.2.iv Morphological and Histological Characterization of ADMCs 
 ADMCs were characterized morphologically with transmitted light microscopy 
using an inverted microscope as used to image ADSCs. ADMCs were further 
characterized histologically using toluidine blue staining. ADMCs were collected by 
removing media from flasks and centrifuging them to pellet the cells. Pelleted cells were 
resuspended in 200 µL of 1x PBS, applied to CytoSpinÔ funnels and spun for 5 minutes 
at 600 rpm in a specialized centrifuge. Slides were then air dried and fixed in methanol 
for one hour. Fixed slides were washed and stained for at least two hours at room 
temperature with a 0.5% toluidine blue solution made with 0.5 N HCl. Following 
staining, slides were washed to remove unincorporated dye. Slides were mounted using 
PermountÔ Mounting Medium and cover slipped with 1.5 thickness cover slips and 
mounting medium was allowed to cure for 15 mins. Cured and mounted slides were 
viewed on an inverted light microscope and images were collected using a CCD camera. 
ADMC were identified by their characteristic heterochromatic staining of the granules. 
Size measurements were determined using software to convert pixel number to length in 
micrometers. 
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III.2.v Immunohistochemical Characterization 
ADMCs were cytocentrifuged onto glass slides and fixed using a 
CytoSpinÔapparatus and methanol as described above. Following methanol fixation for 
one hour, cells were washed twice with 1x PBS then blocked with 1x PBS/5% bovine 
serum albumin (BSA) for 30 minutes. Primary antibody staining was performed 
overnight in dark, humid chambers at 4 °C. Slides were washed twice, then stained with 
fluorescently labeled secondary antibody for two hours, with the Hoechst 33342 being 
added for the final 20 minutes. Labeled slides were washed with 1x PBS once and 
mounted in mounting media and imaged using a Zeiss AXIO Observer Z1 Spinning Disc 
Confocal Microscope. 
 
III.2.vi Phenotypic Characterization of ADMC 
RNA was extracted from ADMC using the Qiagen RNeasy Plus Mini kit per the 
manufacturers recommendation. Reverse transcriptase PCR (RT-PCR) was performed 
using the Qiagen OneStep RT-PCR kit using primers for b-actin, tryptase, chymase, c-
Kit, and FceRIa listed in Table 3.2. Cycling conditions were: 50°C for 30 minutes, 95°C 
for 15 minutes, followed by 35 cycles of 94°C for 45 seconds, 53-63°C for 45 seconds 
(according to primer Tm), 72°C for one minute and a final 10-minute extension at 72°C. 
Upon completion of PCR, samples were applied to a 1% agarose gel containing ethidium 
bromide (EtBr) to allow visualization of DNA. The gel was run for 1 hour at 65 Volts and 
imaged using an agarose gel transilluminator with appropriate filters for ethidium 
bromide.  
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Table 3.2. Primer Sequences Used for RT-PCR of ADMCs. RT-PCR was performed 
on RNA collected from ADMCs to determine the levels of expression of four MC 
specific transcripts. 
 
Gene Direction Sequence (5'→3') 
Tm 
(°C) 
FcɛRI-α Forward CCT TGA ACC CTC CAT GGA ATA G 55.1 
  Reverse CAC TTT GCC CGT ACA GTA GTA G 55 
c-Kit Forward TCT ATG CTC TCGCAC CTT TC 54.5 
  Reverse GAC TCA TGG GCT TGG GAA TA 54.4 
Tryptase Forward 
GCA AAA TAC CAC CTT GGC GCC 
TAC ACG G 65.1 
  Reverse 
GTG ACA CGG GTG TAG ATG CCA 
GGC  63.8 
Chymase Forward CCT GCT GCT CTT TCT CTT GT 55 
  Reverse GCT CCA AGG GTG ACT GTT ATA G 54.9 
β-Actin Forward 
 AAT GTG GCC GAG GAC TTT GAT 
TGC 60.2  
  Reverse 
 AGG ATG GCA AGG GAC TTC CTG 
TAA 59.9  
18s Ribosomal 
Subunit Forward  GCC GCT AGA GGT GAA ATT CT  54.8 
  Reverse  TCG GAA CTA CGA CGG TAT CT 54.8  
 
 
III.2.vii Cell Surface Expression of Mast Cell Markers 
Surface receptor characterization of ADMCs was performed using flow 
cytometry. Cells were recovered by centrifugation at 4°C, washed with 1x PBS/1% BSA, 
and blocked for 30 minutes at 4°C with a 1:400 dilution of normal goat serum. The cells 
were washed and incubated with 5 µg/ml of mouse anti-human FceRI, c-Kit, or the 
mouse control IgG MOPC (Sigma) for two hours at 4°C. After antibody (Ab) labeling, 
the cells were washed and incubated with a 1:100 dilution of F(ab′)2 -FITC-goat anti-
mouse Ab (Jackson Immunology) for 30 minutes at 4°C. After three washes, cells were 
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re-suspended in 400 µL of 1x PBS. The mean intensity of fluorescence was determined 
for at least 105 cells using a FACSAria™III (BD Biosciences). Detector voltages were set 
using unstained ADMCs and the threshold was set automatically by the instrument 
software. At least 100,000 events were recorded for analysis. 
 
III.2. viii Functional Characterization 
In order to determine the functionality of ADMCs, preformed and newly 
synthesized mediator release was measured using the b-hexosaminidase release assay and 
cytokine specific enzyme linked immunosorbent assay (ELISA). Release of preformed b-
hexosaminidase (a surrogate for histamine with similar release kinetics) was determined 
by measuring the amount of a chromogenic substance produced after incubation with an 
engineered b-hexosaminidase substrate. Briefly, ADMCs were activated in a 37°C water 
bath for thirty minutes using 1 µg/mL of the FceRI crosslinking antibody 3B4 in X-
VivoÔ 15. Following activation, cells were pelleted, supernatant was removed, and 
aliquots were loaded onto a multiwell plate. The remaining cell pellet was then 
resuspended and incubated overnight to facilitate measurement of secondary cytokine 
production. The chromogenic, b-hexosaminidase substrate para-Nitrophenyl N-acetyl-b-
D-glucosaminide (PNP) was added to the cell supernatant and incubated for 90 minutes. 
Reactions were terminated by the addition of glycine. The amount of converted substrate 
was quantified spectrophotometrically by measuring the absorbance of the reaction at 405 
nm. In order to determine what percentage of the total intercellular store of b-
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hexosaminidase is released, total b-hexosaminidase levels are measured in cell lysates 
produced by three successive freeze/thaw cycles at -80°C and 37°C, respectively. 
Enzyme linked immunosorbent assay was used to measure newly synthesized 
cytokines generated in response to FceRI challenge. Following overnight incubation, 
cells were pelleted, and supernatants were collected and ELISA was performed as 
described previously [186]. Capture antibodies were immobilized onto plastic multiwell 
plates per manufacturers recommendations in binding buffer. Aliquots of ADMC 
supernatants were loaded into wells with immobilized capture antibody and binding was 
allowed to proceed. Following incubation, wells were washed, and detection antibody 
was added, incubated then washed. Secondary antibodies conjugated with horseradish 
peroxidase (HRP) specific for the detection antibody was used in conjunction with a 
chromogenic substrate. Measurements were taken using a spectrophotometer and 
concentrations in samples were calculated using a standard curve run with each 
experiment. 
 
III.3 Results 
III.3.i ADSC Isolation and Characterization 
  
Human adipose tissue was obtained from two sources and processed as described 
above. Table 3.3 shows the recorded amounts and sources of adipose derived stem cell 
isolation performed. All tissue used in the present study was taken from female subjects, 
the majority of which identified as African American. The average weight of bulk 
resected adipose tissue processed for this study was 195 grams and the amount of 
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liposuction aspirate ranged from 200 mL at the lowest to 1 L at the highest. The number 
of flasks seeded after each preparation was generally 4 T-50 flasks, however smaller 
preps were seeded into fewer flasks. 
 
Table 3.3. Characteristics of Adipose Tissue Processed. Data provided with each 
shipment of adipose tissue was recorded. Data not available is shown as a question 
mark.  
 
 
 
 
All adipose tissue used was normal, but the overall health of the donor was not 
known. It can be presumed, however, that many of the subjects were obese in the case of 
liposuction aspirate donors.  
Bulk Resected Tissue date Mass Age Sex Race Flasks Seeded
8/4/16 50.6 59 F B 4
8/25/16 160 32 F B 4
9/28/17 ? ? ? ? 3
10/6/17 341 ? ? ? ?
11/1/17 147 ? ? ? ?
1/3/18 239 39 F W 4
2/23/18 200 46 F B 2
3/14/18 288 59 F W ?
3/22/18 100 38 F B 2
4/12/18 226 43 F W 3
Liposuction Aspirate Date Volume Age Sex Race Flasks Seeded
2/27/17 700 mL ? ? ? 4
9/27/17 ? ? ? ? 4
4/5/18 1L 58 F ? 4
4/9/18 200 mL ? ? ? 2
 
62 
 
Figure 3.2. Formats of Adipose Tissue Used for ADSC Isolation. Bulk adipose tissue 
(A) was obtained from the Cooperative Human Tissue Network and transported in 
sterile tubs to site of cell isolation. Liposuction aspirate (B) was obtained from local 
plastic surgeons and transported in collecting vessels used during surgery. 
 
 
Figure 3.2 shows the appearance of the two types of tissue upon receipt in the 
laboratory. After mechanical homogenization, enzymatic digestion and washing, freshly 
plated cells grew as adherent fibroblast-like cells as seen in Figure 3.3.  
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Figure 3.3. ADSC Morphology. Light micrographs (A-B) showing ADSC 
morphology. Images obtained using 10x objective and inverted light microscope 
under phase contrast.  
 
 
Cells reached confluence on the flask bottom within approximately three days of 
initial seeding. ADSCs exhibited varying degrees of contact inhibition as evidenced by 
the presence of both epithelial-like cell monolayers and clumps of cells growing on top of 
one another (Figure 3.4).  
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Figure 3.4. ADSCs are Heterogeneous with Respect to Contact Inhibition. ADSCs 
were isolated as previously described from bulk adipose tissue and cultured for 7 
days. ADSCs grew in monolayers (Left) and also formed clumps (Right). 
Magnifications are 40x (Left) and 10x (Right).  
 
 
Cell morphologies of ADSCs are highly complex and varied. As seen in Figure 
3.5, several cell types differing in morphology, or ADSCs at different stages of 
differentiation, were observed in ADSC cultures. These included a myocyte-like 
phenotype (A), large, rounded yet still epithelial cells (B), highly spread out cells with 
what appear to be mitochondrial networks observable in unstained cells (C) and a cuboid, 
endothelial-like phenotype cell that formed “nests” that were distinct from surrounding 
fibroblast-like cells (D). 
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Figure 3.5. Phase Contrast Microscopy of ADSC Cultures. In addition to the 
canonical fibroblast-like morphology of ADSCs other morphologies are observed 
including myocyte-like (A), rounded (B), internally complex (C) and endothelial-like 
(D). Magnifications were 10x (A-B, C) and 40x (D). 
 
 
 Due to the impediments to morphological identification of ADSCs, other markers 
of stem cells were examined such as the tendency of stem cells to exhibit strong 
autofluorescence. As seen in Figure 3.6, ADSCs exhibit a range of autofluorescence 
from very strong, as seen in the cell clump (A) to moderate (white arrows) or none at all 
(red arrows) (B) when illuminated with 488 nm light and monitored for the emission of 
512 nm light. This autofluorescence is most likely the result of one of the following types 
of molecules: NADH [187], lipofuscin [188], or riboflavin [189]. The autofluorescence of 
ADSCs seems to decrease upon induction of differentiation and loss of “stemness” 
A B
CD
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however this assertion is based on personal observation and must be tested empirically 
before autofluorescence can used as a marker of ADSC differentiation.  
 
 
Figure 3.6. Autofluorescent Properties of ADSCs. ADSC were cultured for 7 days. 
Images were collected using a standard fluorescent microscope using standard FITC 
excitation and emission settings (488/512 nm). Large clumps of cells (A) showed the 
highest levels of autofluorescence. ADSCs were heterogeneous with respect to 
autofluorescence (B), white arrows denote autofluorescent ADSCs and red arrows 
denote ADSCs that do not show autofluorescence. Magnifications were 20x (A) and 
4x (B). 
 
 
A B
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Figure 3.7. Mitochondrial Staining of ADSCs. ADSCs were stained with 
MitoTrackerÔ Red. Images were collected at 10x (A) and 40x (B) magnification. 
Mitochondria showed a tubular morphology.  
 
 
 ADSCs were stained with MitoTrackerÔ Red CMXROS and time lapse images 
were taken for 24 hours. Figure 3.7 shows a representative image of one ADSC. ADSCs 
were motile and displayed mitochondrial streaming consistent with a metabolically active 
cell. Mitochondria were observed to be evenly distributed throughout the cell displaying 
a tubular morphology. 
Further immunophenotypic characterization of the ADSC was performed using 
flow cytometry. Figure 3.8 shows density plots obtained from an ADSC experiment. 
Quadrants were determined to identify cells positive (High Fluorescence, lower right 
quadrant) and cells negative (Low Fluorescence, lower left quadrant) for antibody 
staining. Figure 3.9 shows histograms created by gating on the positive population of 
each condition. The ADSC phenotype was determined to be: CD44+CD14-CD105- and 
HLA-ABC+. 
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Figure 3.8. ADSC Immunophenotypic Characterization. Quadrants were 
determined using unstained cells (A) where the lower left quadrant contains the 
negative population and the bottom right the positive population.  
 
 
 
 
Figure 3.9. ADSC Immunophenotypic Characterization - Gating. Histograms shown 
are gated to remove the negative population as determined by the unstained control 
above. 
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III.3.ii ADMC Differentiation and Characterization 
ADSCs were transitioned from ADSC media to complete MC differentiation 
media after a minimum of one week of culture and media was changed approximately 
once per week. Cultures generally started to produce MCs after approximately two weeks 
in differentiation media, however MC production generally started at a relatively low 
rate, which subsequently increased in roughly another two weeks of culture. During the 
initial stages of differentiation, MC-like cells begin to form as large rounded cells with 
visible cellular protrusions that appear to form anchors to the surrounding cells as shown 
in Figure 3.10. It is not clear if the initial MCs arise by budding off adherent cells 
attached to the plastic or if the attached cells themselves release from the tissue culture 
plastic to become MCs.  
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Figure 3.10. Phase Contrast Microscopy of ADSCs Incubated in MC Differentiation 
Media for 14 days. After 14 days small numbers of granulated, spherical cells began 
to appear. As shown, cells were not fully detached from the substrate, but were 
attached via extensions of the cell membrane to surrounding cells. Magnification 
used was 40x.  
 
 
ADMCs were observed to slough off of large aggregates of cells (Figure 3.11) 
that formed in ADSC cultures after addition of differentiation media. 
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Figure 3.11. ADMC. ADMCs in culture growing on monolayer of ADSCs (A) are 
seen growing in clumps. One clump shown in higher magnification (B). Images 
obtained using a 5x objective (A) and a 40x objective (B) and inverted light 
microscope. 
 
 
The ADMC showed a morphology similar to that previously described for human 
skin MCs (connective tissue, MCTC [190]). Specifically, ADMC showed a highly 
spherical morphology with dense, complex granules. As seen in Figure 3.12, the sizes of 
MCs as measured by determining the approximate diameter, showed a large degree of 
variation with the largest cell measuring 27.2 µm in diameter and the smallest cell 
measuring 16 µm in diameter. The average diameter was 21.28 µm ± 3.61. The cause of 
this variation has not yet been determined.  
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Figure 3.12. Size Distribution of ADMCs. The diameters of 44 ADMCs were 
measured and are displayed as a box and whisker plot. 
 
 
As seen in Figure 3.13, toluidine blue staining yielded metachromatic granule 
staining characteristic of MCs. Some variation was observed in the degree of toluidine 
blue staining, which is likely due to the somewhat heterogeneous nature of the MCs 
produced using this protocol.  
 
 
Figure 3.13. Toluidine Blue Staining of MCs. ADMC (A) showed 
characteristic staining similar to hSMC (B) with some variation in the intensity of 
toluidine blue staining.  Magnifications are 10x (A) and 40x (B). 
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A two step, reverse-transcriptase polymerase chain reaction (RT-PCR) protocol was used 
to measure the expression of four MC specific genes: tryptase, chymase, FceRI-a, and c-
kit. In order to restrict the pool of amplified RNA to mature mRNA, a first-step cDNA 
synthesis was performed using Oligo-dT primers. Oligo-dT primers used in first strand 
cDNA synthesis recognize the poly-adenylated tails of fully processed mRNA, removing 
the otherwise complicating unprocessed or non-coding RNAs. cDNA produced in this 
way was then used for traditional PCR using primers designed to amplify small (<1000 
base pairs) specific portions of mRNA corresponding to each gene. Housekeeping genes 
used as loading controls were b-actin and the 18s ribosomal subunit. As seen in Figure 
3.14, expression was observed for all six genes tested. Expression of tryptase and 
chymase mRNA was lower than that of the other four genes tested, however not below 
the limit of detection. Furthermore, there is considerable debate in the literature over the 
“normal” levels of several MC specific transcripts including and especially chymase. 
This is even further confounded by the fact that there are many sub-types of MCs, all of 
which express different compliments of genes and at different levels.   
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Figure 3.14. ADMC Gene Expression. Total RNA was extracted from ADMCs and 
expression of four MC specific genes were analyzed. Two housekeeping genes were 
also measured as controls. 
 
 
Immunohistochemistry verified the expression of tryptase and chymase (Figure 
3.15) suggesting the ADMC are similar to connective tissue MCs or MCTC [191]. Both 
proteins showed characteristic intense punctate staining, indicative of highly concentrated 
secretory vesicles or granules most commonly associated with MCs. In agreement with 
the observation of varying levels of staining produced by toluidine blue, both tryptase and 
chymase showed considerable cell-to-cell variation in expression levels.  
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Figure 3.15. Immunohistochemical characterization of ADMC. ADMC were stained 
using antibodies specific to human tryptase (A) or chymase (B). Secondary antibody 
was labeled with Cy3 and nuclei were stained with Hoechst 333342. 
 
 
Flow cytometric analysis was performed to measure both the presence of cell 
surface markers of MCs and the proportion of cells in ADMC cultures that express them. 
As seen in Figure 3.16, ADMCs showed positive surface expression of FceRI, c-kit and 
HLA-ABC and no surface expression of HLA-DR. In the case of FceRI, several 
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antibodies were tested which gave similar, although not identical expression levels. This 
is not surprising given that these antibodies recognize different epitopes on the FceRI 
molecule which are likely to exhibit varying degrees of accessibility to the antibody 
under the experimental conditions used. HLA profiles of MCs previously reported were 
in agreement with the profile determined for ADMC, namely, ABC+ [192] and DR- [193].  
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Figure 3.16. ADMC Immunophenotypes. ADMCs were stained with antibodies 
specific for the canonical MC surface receptors c-kit (C) and FceRIa (A). HLA 
phenotype (B) was determined using antibodies for two classes of HLA molecules. 
 
 
78 
Functional characterization was performed in response to FceRI-dependent and FceRI-
independent stimuli. As shown in Figure 3.17, ADMC released roughly 40% of total b-
hexosaminidase in response to FceRI challenge, in comparison to almost 80% for the skin 
derived MCs. ADMCs also had considerably higher levels of spontaneous release of b-
hexosaminidase as compared to their skin derived counterparts. ADMCs were also 
analyzed for their ability to degranulate in response to non-FceRI challenge. As seen in 
Figure 3.18, ADMC degranulation was induced by poly-L lysine and the calcium 
ionophore A23187, however not by lipopolysaccharide (LPS) or the peptide fMLP.  
 
 
Figure 3.17. b-hexosaminidase Release from Stimulated MCs. ADMC and hSMCs 
were compared for their ability to degranulate in response to FceRI aggregation by 
the antibody 3B4. 
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Figure 3.18. Non-IgE Mediated Degranulation. b-hexosaminidase release was 
measured from ADMC in response to various non-IgE activators. 
 
 
In order to determine whether or not secondary cytokine production could be 
induced, granulocyte/macrophage-colony stimulating factor production was measured 
using ELISA. As seen in Figure 3.19, ADMC were stimulated to release the contents of 
their granules upon crosslinking of FceRI by the antibody 3B4. Spontaneous release of 
GM-CSF was not detectable for skin derived MCs as compared to roughly 1400 pg/mL in 
ADMCs. 3B4 induced GM-CSF production in hSMCs was roughly 4800 pg/mL as 
compared to 3000 pg/mL for adipose derived MCs. Considerable variation was observed 
in the measurements taken for ADMCs and the difference between spontaneous and 3B4 
induced GM-CSF production that did not reach statistical significance (P = 0.12). The 
spontaneous production of GM-CSF by ADMCs was found to be statistically 
significantly (P=0.03) higher than that of hSMCs. 
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Figure 3.19. GM-CSF Production in Stimulated MCs. GM-CSF production was 
measured by ELISA in ADMCs and hSMCs. Levels are reported in pg/mL and was 
determined using a standard curve. 
 
 
III.4 Discussion 
ADSCs are increasingly being recognized for their highly potent capacity for 
differentiation. While it was originally postulated soon after their discovery in 2001 that 
they would be limited to osteogenic, chondrogenic and myogenic lineages, it is becoming 
increasingly clear that they have much wider applications. Due to the method of isolation 
and culture of ADSCs, the exact nature and origin of these cells is unclear and indeed it is 
unlikely that ADSCs are one cell type. In fact, what we refer to as ADSCs are actually 
the adherent population of the stromal vascular fraction. Some work has been done to 
characterize these cells, however considerable disagreement exists as to the 
immunophenotypic signature of these cells (see Table 2.7). As the use of these cells 
becomes more prevalent, considerable work will need to be done to fully characterize the 
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nature of the SVF and the exact identity of the cells that give rise to any cell 
differentiated from SVF. To this end, time lapse microscopy experiments will need to be 
performed to determine how MCs are produced in culture from ADSCs, in particular 
whether MCs bud off of adherent cells or if the adherent cells themselves release from 
the surface of the flask and become MCs. It was not in the scope of the present work to 
perform this characterization. ADSCs from bulk resected adipose tissue and liposuction 
aspirate collected from adult humans were successfully isolated and cultured. ADSCs 
isolated in this study showed a morphology and an immunophenotype largely consistent 
with those previously reported. One discrepancy between the immunophenotype 
determined for the ADSCs used in this study and some previously reported phenotypes 
was the lack of expression of CD105. As summarized in Table 2.7 there is some 
disagreement about the use of CD105 as a marker of ADSCs as there are studies that 
show both expression and lack of expression of CD105.  
As previously mentioned, there may be a bias induced by the nature of donors 
used in this study, namely that they were all female and many of whom were likely 
obese. ADSCs obtained from obese patients are likely to have biologically distinct 
functions and behaviors to those derived from donors with a normal body mass index. 
Obese adipose tissue is known to be more fibrotic than that of non-obese individuals 
[194] and connections between ADSC function and obesity in humans have been 
reported [195]–[197], including development of glucocorticoid resistance. The impact of 
these differences on the current study, however, is unknown and is unfortunately outside 
its scope. It would be valuable to determine if the health of the donor positively or 
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negatively affects the differentiative capacity of the cells produced as this may have 
implications for future therapies. 
It has been shown here for the first time that functional human MCs can be 
produced through differentiation of ADSCs. ADMC are morphologically, phenotypically 
and functionally similar to other types of MCs. This was determined by direct 
comparison with hSMCs and correlation with previously reported observations in the 
literature.  
The functional and morphological phenotypes of the ADMCs tested were found 
to be somewhat heterogeneous. The exact cause of this heterogeneity is unknown; 
however, it is likely comprised of several factors. It may be due to the more mature 
nature of the hSMCs used for this study. Cultures of hSMCs are not used for experiments 
until several months after their initial isolation, whereas ADMCs are used as they become 
available. It has been previously observed (unpublished observation and personal 
correspondence) that freshly isolated MCs tend to show higher levels of spontaneous 
release of granule contents. Another possible explanation for the differences in 
spontaneous release is that MCs derived from different tissues are phenotypically distinct 
and are very likely to be functionally distinct as well. This supports the hypothesized 
heterogeneity of ADMC cultures. It remains to be seen how this will affect their utility in 
future applications. It should be noted, however, that most types of cultured MCs show 
some level of heterogeneity. Furthermore, MCs in the body cannot be thought of as a 
monolithic population, with different tissue-originating MCs showing high degrees of 
variability in terms of the amount of each protease present in their granules. 
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In conclusion, MCs have been successfully differentiated from stem cells isolated from 
human adipose tissue via a yet to be determined mechanism. These cells are 
phenotypically, functionally and genetically similar to mature tissue derived MCs 
isolated from skin. 
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CHAPTER IV 
APPLICATION OF ADIPOSE DERIVED MAST CELLS TO BREAST CANCER 
AND ALLERGO-ONCOLOGY 
 
IV.1 Introduction 
Breast cancer is the most diagnosed malignancy and the second cause of cancer 
death in women in the United States. The prognosis for breast cancer patients is 
particularly poor in those bearing tumors overexpressing HER2/neu. While treatment of 
patients with advanced breast cancer using the FDA anti-HER2/neu IgG1 Ab (Ab) 
trastuzumab (Herceptin®) leads to improvement in some patients with HER2/neu positive 
tumors, most acquire resistance and eventually die. Thus, improved therapies for 
HER2/neu expressing breast tumors are still urgently needed. In general, Abs used in the 
clinic against cancer are of the IgG class. IgE Abs have several properties that make them 
attractive for cancer therapy such as is its extremely high affinity for its Fc epsilon 
receptor I (FceRI), making it a cytophilic Ab stably bound to the surface of effector cells 
expressing the receptor, such as the tissue-based immune cells MCs (MC). Previous 
studies have shown that high MC densities in breast tumors are associated with favorable 
prognoses suggesting a protective role. Importantly, MC release (upon FceRI stimulation) 
relevant anti-cancer agents such as tumor necrosis factor alpha (TNF-a), uniquely stored 
in human MC granules, as well as granulocyte macrophage colony-stimulating factor 
(GM-CSF). Thus, discovering approaches to target autologous MC to tumor antigens is
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an unrecognized form of a potential particularly effective cancer immunotherapy. 
However, this concept has not been realized given that MC reside in tissue; thus, efficient 
removal, expansion ex vivo, and targeting to tumor sites is not yet feasible. In addition, 
protocols aimed to differentiate MC in vitro using cord blood or peripheral blood as a 
progenitor source are time consuming and limited by the fact that MC maturation cannot 
be fully achieved. 
The overall goal of this project is to investigate a novel autologous, MC-based 
cancer immunotherapy to treat breast cancer. We discovered that human, autologous fully 
differentiated MC can be obtained from adipose tissue and successfully expanded ex vivo. 
These ADMCs, armed with IgE anti-HER2/neu, are activated by HER2/neu human breast 
cancer cells to release GM-CSF and TNF-a, bind to and kill breast cancer cells, and are 
not activated by monomeric (shed) HER2/neu (found in HER2/neu breast cancer patient 
serum).  Our discovery could potentially lead to completely new and innovative ways to 
treat malignancies by harnessing naturally occurring anti-tumor agents within autologous 
(or allogeneic) MC.  
We hypothesized that ADMC effectively armed with anti-HER2/neu IgE Abs 
would target breast cancer cells, degranulate upon antigen (Ag) exposure, and kill the 
breast cancer cells in vitro and in vivo.  Their interaction with the high density of 
HER2/neu Ag expressed on the surface of malignant cells would create a local IgE-
targeted immediate hypersensitivity (anaphylactic) reaction, resulting in acute 
inflammation in the tumor microenvironment and in the rapid killing of cancer cells. 
Further benefit of this strategy is anticipated as the presence of dead tumor cells would 
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allow the effective uptake and presentation of tumor antigens by antigen-presenting cells, 
such as dendritic cells resulting in efficient priming of an adaptive broad-spectrum 
cellular immune response not only to HER2/neu but also to other tumor antigens due to 
epitope spreading. Here, it is shown this strategy is effective in vitro as the ADMC, 
armed with tumor targeting IgE, selectively bind to and kill breast cancer cells upon 
FceRI stimulation. 
 
IV.2 Methods 
IV.2.i SK-BR-3 
The HER2/neu expressing human breast adenocarcinoma cell line, SK-BR-3 was 
purchased from the American Type Culture Collection and cultured in McCoy’s 5A 
Medium supplemented with 10% FBS and 1% Pen/Strep in T-25 flasks in a 37°C 
incubator with a 5% CO2 atmosphere. Media changes were performed every two to three 
days. Flasks were passaged by removing cells from the flask surface using CellStripperÔ 
Cell Dissociation Reagent, pelleting the cells then re-seeding a flask with one fifth the 
original number of cells. Passages were performed when cells reached approximately 
90% confluency. 
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IV.2.ii Cytospins 
 In order to perform immunohistochemistry on cells that are weakly or non-
adherent it is necessary to first immobilize them on a glass substrate. This is most 
commonly achieved using a cytospin apparatus which uses centrifugal force to deposit 
cells onto glass microscope slides. Once attached, slides are briefly air dried, fixed with 
methanol, and incubated with Abs specific for either activated caspase or tryptase 
(5µg/mL) overnight in a humidified chamber kept at 4°C in the dark. Following primary 
Ab staining, slides were washed to remove any unbound primary Ab. Secondary Ab 
staining was performed for 2 hours also at 4°C in the dark in a humidified chamber, after 
which slides were washed and mounted under coverslips and allowed to cure overnight. 
Images were collected using a Zeiss spinning disc confocal microscope. 
 
IV.2.iii ADMC Co-Culture with Breast Cancer Cells - ADCC 
Initial experiments were performed using two cell stains, MitoTrackerÔ Red to 
stain SK-BR-3 cells and MitoTrackerÔ Green to stain ADMC. These experiments lasted 
six hours each. In order to incorporate propidium iodide staining into the protocol, in 
subsequent experiments CellTracker Deep Red was used to stain ADMC and 
MitoTrackerÔ Green was used to stain SK-BR-3 cells and experiments lasted between 
48 and 72 hours. For co-culture experiments, ADMCs were collected, pelleted then 
resuspended in X-Vivo supplemented with rhSCF but without IgE and plated in a 24 well 
cell culture plate. ADMCs were maintained in media without IgE for a minimum of 4 
days to allow IgE bound to FceRI molecules on the cell surface to be released. This step 
 
88 
was added to ensure that the receptors were not saturated with IgE upon addition of the 
Abs being investigated. SK-BR-3 cells were removed from flasks as described above. 
Cells were seeded into 60 mm plastic petri dishes with cover slip bottoms at a density of 
either 50,000 or 160,000 cells/3 mL, depending on the experiment. SK-BR-3 cells were 
allowed to attach and grow for 24 hours. After at least four days of incubation, 160,000 
ADMCs per condition were collected from the non-IgE media were incubated with either 
1 µg/mL anti-HER2 or control IgE. ADMC were incubated with 2 µM CellTracker Deep 
Red or MitoTrackerÔ Green for one hour on ice. Media was removed from SK-BR-3 
cells and replaced with fresh media containing 2 µM MitoTrackerÔ Green or Red for 30 
minutes at 37°C in the dark. Following 30 minutes of staining, SK-BR-3 cells were 
washed once with fresh media to remove unincorporated dye and 1 mL of fresh media 
was added to the plate.  Following staining and activation with IgE, ADMC were pelleted 
and washed once to remove unincorporated dye and unbound IgE, then resuspended in 1 
mL of SK-BR-3 media and added to the plate containing SK-BR-3 cells. A final 1 mL of 
SK-BR-3 media containing Propidium Iodide (in some experiments) is added to the plate 
to yield a final concentration of 25 µg/mL. Imaging was begun as soon as possible, 
usually five minutes, but not exceeding 20 minutes. Images were collected using a Zeiss 
spinning disc confocal microscope fitted with an environmental incubation chamber 
designed to maintain an environment of 37°C and 5% CO2. MitoTrackerÔ Green was 
imaged using a 488 nm laser at 2% intensity, propidium iodide was imaged using a 561 
nm laser at 3% intensity and CellTracker Deep Red was imaged using a 639 nm laser at 
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10% intensity. For each time point and, in each color, images were taken from 10 focal 
planes with a spacing of 12.73 µm.  
 
IV.2.iv ADMC Mediator Induced Cell Killing (MICK) 
 SK-BR-3 cell death induced by mediators released from stimulated ADMCs was 
measured using a similar protocol as described for ADMC-ADCC. Mediator release from 
at least one million ADMCs was induced as described for the b-hexosaminidase release 
assay. Briefly, ADMC were collected, counted and pelleted by centrifugation. Cells were 
then incubated with 1 µg/mL of the FceRI Ab (3B4) overnight and allowed to release 
preformed as well as newly generated mediators. Following incubation, cells were 
pelleted, and supernatants were removed. Supernatants were filtered through 0.22 µm 
filters to ensure that no cells were present in mediator preparations. SK-BR-3 cells were 
seeded into 60 mm cover slip bottom petri dishes at a density of 160,000/3 mL and 
allowed to attach and grow for 24 hours before use. On the day of the experiment media 
was removed from cells and replaced with fresh media containing 2 µM MitoTrackerÔ 
Green and incubated at 37°C in the dark for 30 minutes. Following staining, cells were 
washed once to remove unincorporated dye and replated in 3 mL of fresh media 
containing 25 µg/mL of propidium iodide and between 500 and 1000 µL of mediator 
preparations. Images were collected as described above with the exception of the 639 nm 
laser which was not used.  
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IV.2.v Extended Time Course Experiments 
 For extended time course experiments lasting more than 72 hours, SK-BR-3 cells 
were prepared similarly to previous experiments with the exception of the omission of 
any cell-labeling dyes. Propidium iodide was added to the media as above and images 
were collected at the beginning of each experiment and at various timepoints thereafter. 
Unlike previous experiments in which cells were maintained on the microscope in an 
environmental control chamber, for extended time course experiments the plates were 
kept in a separate incubator and removed for imaging. 
 
IV.3 Results 
IV.3.i ADMC Co-Culture with Breast Cancer Cells 
 ADMC co-culture experiments were performed to investigate the ability of MCs 
targeted through Trastuzumab IgE to induce cytotoxicity in SK-BR-3 cells. In the first 
co-culture experiments, ADMC were stained with MitoTrackerÔ Green and sensitized 
with either Trastuzumab IgE or non-specific psIgE and SK-BR-3 cells were stained with 
MitoTrackerÔ Red, and observed over the course of six hours, as seen in representative 
images from several time points in Figure 4.1. During this time, interactions were 
observed in cells incubated with both specific and non-specific Abs. As seen in Figure 
4.2, dye was often observed to transfer from the breast cancer cells into ADMC, however 
dye was not regularly observed to pass from MCs into breast cancer cells. In experiments 
using Trastuzumab IgE, ADMC were observed to translocate considerable distances 
toward breast cancer cells (Figure 4.3), whereas this translocation was not observed 
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during the six-hour experiments with non-specific IgE. Another phenomenon only 
observed in the trastuzumab IgE experiment was the induction of polarization of ADMC 
staining, possibly indicative of MC activation through IgE-bound FceRI binding to 
HER2/neu expressing breast cancer cells (Figure 4.4). 
 
 
Figure 4.1. Six-Hour ADMC and SK-BR-3 Co-Culture. 259,000 ADMC were 
sensitized with 1 µg/ml of a non-specific control IgE (A-C) or trastuzumab IgE (D-F) 
and stained with MitoTrackerÔ Green. The MitoTrackerÔ Green-loaded ADMC 
were added to adherent SK-BR-3 (105-106) that had been pre-stained with 
MitoTrackerÔ Red and time lapse video taken every five minutes over six hours at 
10x magnification. 
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Figure 4.2. ADMC-to-SK-BR-3 Dye Transfer. ADMCs were sensitized with 1 µg/mL 
non-specific IgE for 1 hour and stained with MitoTrackerÔ Green. SK-BR-3 cells 
were stained with MitoTrackerÔ Red. White and yellow arrows indicate ADMC-
SK-BR-3 interactions. ADMCs are seen to uptake MitoTrackerÔ Red from SK-BR-
3 cells. Images were collected every five minutes for six hours at a magnification of 
10x. 
 
 
 
 
Figure 4.3. ADMC Binding of SK-BR-3 Cells. 259,000 ADMC were sensitized with 1 
µg/ml of trastuzumab IgE and stained with MitoTrackerÔ Green. The 
MitoTrackerÔ Green-loaded ADMC were added to adherent SK-BR-3 (105-106) 
that had been pre-stained with MitoTrackerÔ Red and time lapse video taken over 
six hours. The white circular boundaries and arrows represent starting point and 
tracking of ADMC (green) at time 0 to SK-BR-3 (red) binding over five of the six 
hours at 10X magnification. 
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Figure 4.4. Cytoplasmic Polarization of ADMC. ADMCs were sensitized with 1 
µg/mL Trastuzumab IgE for 1 hour and stained with MitoTrackerÔ Green. SK-
BR-3 cells were stained with MitoTrackerÔ Red. White arrow shows ADMC 
induced to polarize cytoplasm towards SK-BR-3 cell. Images were collected every 
five minutes over the course of six hours at 10x magnification. 
 
 
The initial protocol for monitoring SK-BR-3 cell killing by ADMC used ADMC 
labeled with MitoTrackerÔ Green, unlabeled SK-BR-3 and propidium iodide in the 
media and co-cultures were monitored over the course of 18 hours. As seen in Figure 
4.5, over the course of the experiment the dye was observed to stain the cancer cells that 
were initially unstained. The problem of dye leakage prompted the further augmentation 
of the initial protocol to a more cell-permanent dye, CellTrackerÔ Deep Red. As can be 
 
94 
seen in Figures 4.6, using this system, dye leakage was eliminated, and it became 
possible to increase experiment durations to up to 72 hours. 
 
 
Figure 4.5. MitoTrackerÔ Green Leakage from ADMC. Roughly 420,000 ADMCs 
were sensitized with 1 µg/mL Trastuzumab IgE for 1 hour and stained with 
MitoTrackerÔ Green. Images were collected every 15 minutes for 18 hours at 10x 
magnification. 
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Figure 4.6. Three Color ADMC-SK-BR-3 Co-Culture Experiments. 160,000 ADMC 
were sensitized with Trastuzumab IgE (A-C) or non-specific IgE (D-F) at 1 µg/mL 
for one hour and stained with CellTrackerÔ Deep Red. 160,000 SK-BR-3 cells were 
stained with MitoTrackerÔ Green and propidium iodide was added to culture 
media. Images were collected every hour for 72 hours at a magnification of 10x. 
 
 
ADMC sensitized with Trastuzumab IgE induced PI uptake in cancer cells, 
however PI uptake was also induced by MCs sensitized with control IgE. In at least one 
instance in which MCs were co-cultured with breast cancer cells for long periods, a MC 
was observed to phagocytose a cancer cell (Figure 4.7). Cancer cell phagocytosis was an 
uncommon occurrence that was observed in experiments using Trastuzumab IgE and 
psIgE.  
 
 
96 
 
Figure 4.7 Phagocytosis of SK-BR-3 Cell. Roughly 140,000 ADMCs were sensitized 
with a non-specific IgE for one hour and stained with CellTrackerÔ Deep Red. 
160,000 SK-BR-3 cells were stained with MitoTrackerÔ Green. Selected images 
show phagocytosis of SK-BR-3 cell by an ADMC. White arrow indicates cells of 
interest. Images were collected every hour for 72 hours at 10x magnification. 
 
 
IgE sensitized ADMCs were co-incubated with SK-BR-3 cells overnight then 
collected and used to make cytospin preparations that were then probed with Abs specific 
for activated caspase and tryptase. As seen in Figure 4.8, IgE-sensitized ADMC induced 
a significant level of caspase activity. Figure 4.9 shows that caspase activation was 
almost non-existent in non-stimulated-ADMC co-cultures with SK-BR-3 cells.   
 
BA
ED
C
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Figure 4.8. Induction of Apoptosis in SK-BR-3-ADMC Co-Cultures. Trastuzumab 
IgE-sensitized ADMC (7.5x104) were incubated with SK-BR-3 (1x105) for 72 hours, 
cytospins made, fixed, and incubated with Alexa FluorÔ 488 labelled, mouse anti-
human tryptase (green) along with Alexa FluorÔ 647 labelled, mouse anti-human 
caspase 3 (red).  A-D were collected using 20x magnification, E-H were collected 
using 40x magnification. 
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Figure 4.9. Non-Specific IgG Controls. Trastuzumab IgE-sensitized ADMC 
(7.5x104) were incubated with SK-BR-3 (1x105) for 72 hours, cytospins made, fixed, 
and incubated with Alexa FluorÔ 488 labelled, mouse anti-human tryptase (green) 
along with Alexa FluorÔ 647 labelled, isotype control IgG for caspase 3 Ab (red). A-
D were collected using 20x magnification, E-H were collected using 40x 
magnification. 
 
 
IV.3.ii ADMC Mediator Induced Cell Killing 
 To further explore the mechanism of ADMC induced cytotoxicity in SK-BR-3 
cells, the participation of cells as opposed to substances released from cells was 
examined. ADMCs were stimulated with the FceRI crosslinking Ab 3B4 overnight and 
supernatants were collected and added to dishes containing SK-BR-3 cells in the presence 
of propidium iodide. As seen in Figure 4.10, mediators from FceRI-challenged MCs 
induced low levels of apoptosis as determined by propidium iodide uptake at successive 
time points. Apoptosis determined through activated caspase staining showed higher 
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levels of apoptosis in SK-BR-3 cells treated with FceRI-challenged MC supernatants 
(Figure 4.11) than in cells treated with non-challenged ADMC supernatants (Figure 
4.12).  
 
 
Figure 4.10. ADMC-MICK of SK-BR-3 Cells. 160,000 SK-BR-3 cells were stained 
with MitoTrackerÔ Green for 30 minutes. Propidium iodide was added to the 
culture media in addition to roughly 500 µL of FceRI-challenged MC supernatant. 
Images were collected once every hour (A-C) or every 30 minutes (D-F) for 72 hours 
at a magnification of 10x (A-C) or 20 x (D-F).  
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Figure 4.11. Induction of Apoptosis in SK-BR-3 by Activated MC Mediators. 
ADMC (1.3x106) were challenged with optimal concentrations of anti-FceRI 
stimuli (70% release) for 24 hours and supernatants (no cells) from these ADMC 
were incubated with SK-BR-3 cells (105) for 72 hours, cytospins prepared, fixed, and 
incubated with Alexa FluorÔ 647 labelled, anti-human caspase 3 (red). Images were 
collected at 20x (A) and 40x (B-D).  
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Figure 4.12. Induction of Apoptosis in SK-BR-3 by Non-Activated MC 
Supernatants. Media (no cells) from non-FceRI challenged ADMC were incubated 
with SK-BR-3 (105) for 72 hours, cytospins prepared, fixed, and incubated with 
Alexa FluorÔ 647 labelled, anti-human caspase 3 (red). Images were collected at 
20x (A-B) and 40x (C-D).  
 
 
 
 
 
 
102 
IV.3.iii 72+ Hour Experiments 
In an effort to more accurately quantify the uptake of PI over longer time spans, a 
protocol was created wherein cells were grown in an incubator and removed at various 
time points for imaging. Cells were grown for 96 hours in the presence of supernatants 
from FceRI-challenged or non-challenged MCs and images were collected over the 
course of the experiment. Supernatants from FceRI-challenged MCs induced a loss of 
membrane integrity in breast cancer cells at a higher level than did control supernatants.  
 During the first experiment, both ADCC and MICK were investigated. 
Measurements were taken at day 0, day 5 and day 7 and as illustrated in Figure 4.13, 
although the treated cells showed higher levels of PI uptake, both control samples also 
showed a statistically significantly higher level of PI uptake at day 7 vs day 5.  
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Figure 4.13. Quantification of Cell Membrane Integrity Loss Over Seven Days. 
160,000 SK-BR-3 cells were cultured in glass-bottom dishes with propidium iodide 
and either supernatant (spontaneous, 3B4) or ADMC sensitized with an IgE.  Dishes 
were imaged at four locations for every time point and averages were calculated (* 
denotes P < 0.05, ** denotes P < 0.005, ns denotes P > 0.05). P values calculated 
using type 2, 2 tailed students t-test. 
 
 
 In the next experiment ADCC was measured over the course of 14 days. As can 
be seen in Figure 4.14, the trend observed after 7 days continued to day 14.   
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Figure 4.14. Quantification of Cell Membrane Integrity Loss Over 14 Days. 160,000 
SK-BR-3 cells were cultured in glass-bottom dishes with propidium iodide and 
ADMC sensitized with an IgE.  Dishes were imaged at four locations for every time 
point and averages were calculated (* denotes P < 0.05, ** denotes P < 0.005, ns 
denotes P > 0.05). P values calculated using type 2, 2 tailed students t-test. 
 
 
 In the third experiment the contribution of non-sensitized MCs was investigated 
and compared to ADCC over the course of four days. As can be seen in Figure 4.15, 
after four days non-sensitized MCs induced a small but statistically significant increase in 
PI uptake. 
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Figure 4.15. Quantification of Cell Membrane Integrity Loss Over Four Days. 
160,000 SK-BR-3 cells were cultured in glass-bottom dishes with propidium iodide 
alone (no MC), supernatant (spontaneous, 3B4), non-sensitized ADMC (no IgE) or 
ADMC sensitized with an IgE.  Dishes were imaged at four locations for every time 
point and averages were calculated (* denotes P < 0.05, ** denotes P < 0.005, ns 
denotes P > 0.05). P values calculated using type 2, 2 tailed students t-test. 
 
 
 In the final experiment, MICK was investigated over the course of four days. As 
can be seen in Figure 4.16, FceRI-challenged MC supernatants induced a significantly 
significant increase in PI uptake after four days, whereas neither control condition did. 
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Figure 4.16. Quantification of Cell Membrane Integrity Loss Over Four Days. 
160,000 SK-BR-3 cells were cultured in glass-bottom dishes with propidium iodide 
and either fresh media (AimV), supernatant from non-stimulated ADMC 
(spontaneous), or FceRI-challenged ADMC (3B4).  Dishes were imaged at four 
locations for every time point and averages were calculated (* denotes P < 0.05, ** 
denotes P < 0.005, ns denotes P > 0.05). P values calculated using type 2, 2 tailed 
students t-test. 
 
 
IV.4 Discussion 
ADMC induced cytotoxicity was observed in co-cultures of MCs and breast 
cancer cells with a large degree of heterogeneity. Cell death was most commonly 
observed after roughly 96 hours, although interactions between MCs and breast cancer 
cells were observed earlier very soon after the introduction of MCs to the dish. Cell-cell 
interactions appeared to be partly Ab mediated and partially independently of Ab 
specificity as control IgE-laden MC were also observed to interact with breast cancer 
cells. 
The first set of experiments were performed over the course of six hours, during 
which time interactions were observed between ADMCs and SK-BR-3 cells regardless of 
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the Ab used to activate the ADMC. However, considerably more interactions were 
observed when anti-HER2 IgE was used. In addition to interactions between cells such as 
localization or dye transfer, in at least one instance a polarization of cytoplasmic contents 
of a MC towards a cancer cell was observed. It is not clear if this represents something 
akin to an immunological synapse [198], a degranulatory synapse [199], or something 
else altogether. No specific staining was used that would confirm or deny the presence of 
molecules indicative of a synapse as this was not feasible using the live-cell imaging 
protocol used for these studies. Future experiments in which synapse formation is 
investigated should be undertaken. 
Another interesting phenomenon that was directly observed at least once was 
phagocytosis of a cancer cell by a MC. MC phagocytosis of breast cancer cells in vivo 
has been suggested, and there is circumstantial evidence supporting this [200]. The 
degree to which cancer cell phagocytosis by MCs represents a physiologically [201] or 
therapeutically relevant process will require further investigation, however it is consistent 
with reported antigen presenting cell capabilities of MCs [202]. 
It is interesting to note that MCs seem to have a significant level of basal cancer 
cell cytotoxicity as evidenced by the induction of cell killing by supernatants from non-
FceRI-challenged MCs, non-sensitized ADMC or ADMC sensitized with non-specific 
IgE. This is in contrast to media alone which failed to induce statistically significant 
levels of cell death. It is not clear what is responsible for this observation, and further 
research will be necessary to determine if the mechanism of cytotoxicity is the same or 
different from those responsible for ADCC and MICK. 
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One shortcoming of these initial experiments was the lack a condition with no IgE. While 
a control IgE, psIgE was used, the exact nature of this control IgE is unknown. Originally 
collected from a patient with an IgE-overproducing malignancy, this IgE has not to the 
best of the knowledge of the author been characterized for specificity or affinity of 
binding. Given this uncertainty it would be of interest to examine a second non-specific 
IgE, as the possibility exists that the interaction of monomeric IgE with FceRI has a 
stimulatory effect on ADMC.   
Another shortcoming of this experimental setup was the use of propidium iodide 
rather than a more specific marker of apoptosis. Propidium iodide is in fact a marker of 
cell membrane integrity loss, which is associated with cell death, but may also be 
influenced by other factors. It will be necessary to replicate these results in the future to 
address these concerns. Dyes that can be used in live-cell time lapse imaging do exist and 
were purchased, specifically CellEventÔ Green. Preliminary experiments suggest that it 
may be possible to replace propidium iodide with CellEventÔ Green. As shown in 
Figure 4.17, CellEventÔ Green staining often overlaps with PI staining, however some 
differences exist. It was not possible to incorporate its use into the current set of 
experiments; however, it will be interesting to investigate their utility in the future.  
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Figure 4.17. CellEventÔ Green Test. SK-BR-3 cells were stained with 
CellTrackerÔ Deep Red, and PI and CellEventÔ Green were added to the 
culture media. Cells were grown for 24 hours and images were taken at 40x 
magnification. 
 
 
Another possible change to the current experimental setup would be the use of 
flow cytometry as opposed to confocal microscopy as a means to quantify staining by the 
apoptosis marker of choice. As with CellEventÔ Green, some preliminary experiments 
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were performed to test the feasibility of this method. As shown in Figure 4.18, two 
populations of cells could be differentiated based on PI staining. 
 
 
Figure 4.18. Flow Cytometric Analysis of ADCC Experiments – Trastuzumab-IgE. 
Following image collection at hour 96 of ADCC experiments, cells were collected 
using CellStripperÔ and analyzed using a FACSAriaIIIÔ flow cytometer to 
measure PI fluorescence. Filled in gray curve represents non-specific IgE control, 
black line represents trastuzumab-IgE sensitized ADMC-SK-BR-3 co-cultures. 
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Figure 4.19. Flow Cytometric Analysis of ADCC Experiments – C6MH3-B1. 
Following image collection at hour 96 of ADCC experiments, cells were collected 
using CellStripperÔ and analyzed using a FACSAriaIIIÔ flow cytometer to 
measure PI fluorescence. Filled in gray curve represents non-specific IgE control, 
black line and dark grey lines represent C6MH3-B1-IgE sensitized ADMC-SK-BR-3 
co-cultures. 
 
 
The exact role that MCs play in the progression, maintenance and spread of 
tumors in the human body remains largely unclear, due to the seemingly contradictory 
results of studies of the effect that MCs have on tumors. While this may be in part due to 
differences in experimental setups, it is also likely due to the highly pleiotropic nature of 
MCs and their ability to behave in many often starkly contrasting context-specific ways. 
It is likely that there are certain malignancies that would benefit from the increased 
presence of MCs while other others may be exacerbated by their presence. The current 
study focused on HER2 positive breast cancer as it is one of the types of tumors in which 
the presence of MCs is associated with higher survival rates. It remains to be seen if this 
type of therapy could be utilized in tumors not traditionally associated with MCs having a 
positive effect on survival based on IgE-mediated targeting.  
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The current study represents a proof-of-principle for the use of MCs differentiated from 
human adipose tissue in an allergo-oncological therapy. A significant amount of research 
is still required to determine the mechanisms of ADMC killing of breast cancer cells and 
whether or not this technology will function in vivo. If successful, however, this 
technology represents a new strategy for treating tumors through the selective targeting of 
tumor specific antigens with IgEs that mediate the targeting and release of tumor-killing 
mediators from MC.
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CHAPTER V 
FUTURE APPLICATIONS 
 
V.1 Definition of Conditioned Media 
 One of the most pressing outstanding questions is the exact composition of 
conditioned mast cell media and more specifically which are the most important 
components for the purposes of differentiation of MCs. Determining this will not be a 
trivial undertaking as it is likely to contain many different molecules, only some of which 
are likely to play a role in the differentiation of ADSCs into MCs. Furthermore, it is 
possible that all batches of conditioned mast cell media are not identical and determining 
the degree of batch-to-batch variation will also be important. Ideally, in the future it 
would be beneficial to use a defined media supplemented with only those growth factors 
necessary for MC differentiation. Preliminary proteomic studies have been initiated and 
have produced some results, summarized in Table 5.1. These data are intriguing; 
however, a more exhaustive and comprehensive analysis is likely required that will 
include the analysis of non-protein-based components of the MC secretome including but 
not limited to lipids, arachidonic acid derived molecules and nucleic acids. Of particular 
interest will be the analysis of exosomes secreted by MC and their effect on ADSC 
differentiation. 
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V.1.i Haptoglobin 
One of the most interesting results from the initial proteomic screen was the 
presence of haptoglobin. Of the ten proteins identified in the initial proteomic screen, 
haptoglobin was the third most abundant. Haptoglobin is traditionally understood to be a 
serum protein that binds free hemoglobin in the blood, however it is increasingly being 
recognized for its role in immune functions such as B cell differentiation [203], B cell 
behavior [204], Th2 cytokine production in T cells [205], neutrophil function [206] and 
the growth of the human MC line HMC-1 [207]. 
Until very recently haptoglobin was presumed to be produced only by the liver 
and secreted into the blood. While it is of course true that haptoglobin is synthesized in 
large quantities by the liver, it was determined in 2006 that haptoglobin is also produced 
by human neutrophils and stored in cytoplasmic granules [208]. It was later shown that a 
form of haptoglobin is produced by leukocytes in mice [203]. It is therefore conceivable 
that haptoglobin may also be produced by MC despite the fact that studies of haptoglobin 
expression have as of yet failed to identify MC as a source. This possibility is highlighted 
by a 2013 study in which the authors conclude that haptoglobin was produced only by the 
liver, pancreas and bone marrow [209], however skin was not among the tissues 
examined. 
While no data exist showing that haptoglobin plays a role in the differentiation of 
MC, several pieces of evidence suggest that it could. First and foremost haptoglobin has 
been shown to bind to MC in vitro [207]. While the effect reported was to inhibit growth, 
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as determined the incorporation of radiolabeled nuclides into the DNA of these cells, the 
effect of haptoglobin on the differentiation of MC from their precursors remains 
unexplored. It is also of particular interest that neutrophils both produce, store and 
presumably secrete haptoglobin [208] and inhibit neutrophil functions [206], showing 
that in a least one instance haptoglobin can have an autocrine function.  
Direct evidence of the interaction between haptoglobin and ADSCs is lacking, 
however several studies have suggested a connection between the two in the context of 
allograft tolerance in a rat model [210], [211]. A detailed study of the effects of 
haptoglobin of the differentiative capacity of ADSCs is needed to determine the 
relevance of the finding of haptoglobin in conditioned mast cell media. 
 
V.2 In vivo Studies 
 The logical extension of the research performed in this study on the application of 
ADMC to allergo-oncology will be to perform in vivo studies. In vivo studies are most 
commonly carried out first in mice, then in higher organisms. A mouse model of human 
HER2/neu expressing breast cancer has been developed and used to test the ability of 
anti-HER2/neu IgE to decrease tumor burden in mice with humanized FceRI receptors. 
This same model will be used to test the ability of anti-HER2/neu IgE-sensitized ADMC 
to locate and kill human breast cancer cells. 
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V.3 MC Interactions  
 An important question that remains is how MCs interact with the multitude of cell 
types they encounter in vivo and how these interacts may influence the use of MCs for 
allergo-oncology. One of the most exciting future directions for the research presented in 
this study is the investigation of possible interactions between MC and T cells, and the 
extent to which IgE targeting can play a role. It has been conclusively shown that MC can 
act as antigen presenting cells (APCs) for T cells [202].  
 It is thought that the cell type that is ultimately responsible for the majority of 
cancer cell killing in vivo is the T cell. T cell-based therapies are one of the most highly 
investigated methods of chemotherapy currently under investigation. T cell therapies can 
be placed in to two broadly defined categories, either monoclonal antibody (mAb) based 
or adoptive cell transfer (ACT) based [212]. The two most common targets of mAb-based 
therapies are PD-1 and CTLA4, both of which play roles in checkpoint control of T cell 
activity. Inhibition of these molecules using inhibitory mAbs has been shown to promote 
a T cell response that in many cases is able to eradicate the tumor burden. the exact 
mechanism by which checkpoint inhibition functions remains unknown, however there is 
some circumstantial evidence that may support a role for MC in this process. The first 
observation that may support the notion of MC participation in this T cell response is that 
MC express many of the molecules that are found on antigen presenting cells such as 
dendritic cells, which are commonly thought of as the cells responsible for presenting 
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tumor antigens to T cells. These include OX40, CD40 and HLA-DR, the latter two of 
which are inducible by interferon-g.  
 A recently published study describing a local immunotherapy for spontaneous 
malignancies provides an interesting possible connection between MCs and T cell 
checkpoint inhibition [213]. In this study, a combination of molecules was used to induce 
T cell targeting of tumors as well as a type of immunological memory allowing treated 
animals to respond to subsequent tumor development. The molecules used in this study 
were a ligand for TRL9, unmethylated CpG DNA and an anti-OX40 antibody. These 
molecules are interesting when considering the role of MCs in this process as MCs have 
been previously shown to express both TLR9 [39] and OX40 [214]. 
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Table 5.1 Proteomic Analysis of CMCM Proteins. 
 
Protein Pseudonyms Ab
un
da
nce 
Number 
of 
Unique 
Peptides 
Function Cellula
r 
Localiz
ation 
Tissue 
localization 
Reported MC 
Interactions 
Serum 
Albumin  
ALB, HAS 62.
5-
86.
1% 
24 Colloidal osmotic 
pressure 
maintenance 
Extrace
llular 
Serum - (Liver) Fragments of 
ALB induce 
degranulation via 
MRGPRX2 
Apolipoprotei
n A2 
APOA2 37
% 
2 Major 
component of 
HDL, lipoprotein 
homeostasis  
Extrace
llular 
Serum - (Liver, 
Intestine) 
Degraded by MC 
chymase in 
mouse models 
Haptoglobin BP, HPA1S 7.5
0% 
4 Serum protein, 
binds free 
hemoglobin 
Extrace
llular, 
granul
es 
Serum - (Liver, 
arteries, lung, 
adipose, 
leukocytes) 
Inhibits HMC-1 
growth, Induced 
by IL-6 
Plasma 
protease C1 
inhibitor 
SERPING1 4.8
0% 
3 Inhibits 
complement 
protease C1 
Extrace
llular 
Serum - 
(Multiple, Liver) 
Expressed by 
BMMCs, 
Serotransferri
n 
Transferrin 0.8
0% 
2 Ferric iron 
binding, iron 
transport 
Extrace
llular 
Serum - (Liver, 
brain, adipose) 
Inhibits 
histamine 
production 
Inactive 
phospholipase 
C-like protein 
2 
PLCL2, 
phospholipase C-
epsilon 2 
0.6
0% 
1 GABA Receptor 
regulation, 
Phosphoinositol 
signaling 
Perinu
clear 
Multiple (27) None 
F-box only 
protein 50 
Non-specific 
cytotoxic cell 
receptor protein 1 
homolog, NCCRP1 
0.3
0% 
1 E3 ubiquitin 
ligase pathway 
component 
Cytopl
asm 
Esophagus, 
skin, urinary 
bladder 
None 
Ankyrin 
repeat 
domain-
containing 
protein 23 
Diabetes-related 
ankyrin-repeat 
protein (DARP), 
CARP3 
0.2
0% 
1 Glucose 
metabolism, 
Skeletal muscle 
development 
Nucleu
s 
Heart, Brown 
Adipose, 
Skeletal Muscle 
None 
Protein 
disulfide-
isomerase A2 
Pancreas-specific 
protein disulfide 
isomerase, PDIp 
0.1
0% 
1 Protein folding, 
estradiol binding 
Endopl
asmic 
reticul
um 
Pancreas, GI None 
N-
acetylmuramo
yl-L-alanine 
amidase 
PGLYRP2, tagL, 
PGRPL 
0.1
0% 
1 Hydrolyzes 
peptidoglycan 
Extrace
llular 
Serum - (Liver, 
testes) 
None 
 
 
 
 
119 
REFERENCES 
 
 
[1] E. Crivellato, C. A. Beltrami, F. Mallardi, and D. Ribatti, “Paul Ehrlich’s doctoral 
thesis: A milestone in the study of mast cells,” Br. J. Haematol., vol. 123, no. 1, 
pp. 19–21, 2003. 
[2] P. Ehrlich, “Beitrage Zur Kenntis der Anilinfarbugen und ihrer Verwendung in der 
Mikroskepischen Technik.pdf,” 1877. 
[3] G. Varricchi, M. R. Galdiero, S. Loffredo, G. Marone, R. Iannone, G. Marone, and 
F. Granata, “Are mast cells MASTers in cancer?,” Front. Immunol., vol. 8, no. 
APR, pp. 1–13, 2017. 
[4] T. J. Welsh, R. H. Green, D. Richardson, D. A. Waller, K. J. O’Byrne, and P. 
Bradding, “Macrophage and mast-cell invasion of tumor cell islets confers a 
marked survival advantage in non-small-cell lung cancer,” J. Clin. Oncol., vol. 23, 
no. 35, pp. 8959–8967, 2005. 
[5] J. K. Chan, A. Magistris, V. Loizzi, F. Lin, J. Rutgers, K. Osann, P. J. DiSaia, and 
M. Samoszuk, “Mast cell density, angiogenesis, blood clotting, and prognosis in 
women with advanced ovarian cancer,” Gynecol. Oncol., vol. 99, no. 1, pp. 20–25, 
2005. 
[6] S.-Y. Tan, Y. Fan, H.-S. Luo, Z.-X. Shen, Y. Guo, and L.-J. Zhao, “Prognostic 
significance of cell infiltrations of immunosurveillance in colorectal cancer,” 
World J. Gastroenterol., vol. 11, no. 8, pp. 1210–1214, 2005. 
[7] A. B. Rajput, D. A. Turbin, M. C. Cheang, D. K. Voduc, S. Leung, K. A. Gelmon, 
C. B. Gilks, and D. G. Huntsman, “Stromal mast cells in invasive breast cancer are 
a marker of favourable prognosis: A study of 4,444 cases,” Breast Cancer Res. 
Treat., vol. 107, no. 2, pp. 249–257, 2008. 
[8] S. Dabiri, D. Huntsman, N. Makretsov, M. Cheang, B. Gilks, C. Badjik, K. 
Gelmon, S. Chia, and M. Hayes, “The presence of stromal mast cells identifies a 
subset of invasive breast cancers with a favorable prognosis,” Mod. Pathol., vol. 
17, no. 6, pp. 690–695, 2004. 
[9] F. della Rovere, A. Granata, D. Familiari, G. D’Arrigo, B. Mondello, and G. 
Basile, “Mast cells in invasive ductal breast cancer: different behavior in high and 
minimum hormone-receptive cancers,” Anticancer Res, vol. 27, no. 4B, pp. 2465–
2471, 2007. 
[10] K. N. Rao and M. A. Brown, “Mast cells: Multifaceted immune cells with diverse 
roles in health and disease,” Ann. N. Y. Acad. Sci., vol. 1143, pp. 83–104, 2008. 
[11] Y. Ishijima, S. Ohmori, and K. Ohneda, “Mast cell deficiency results in the 
accumulation of preadipocytes in adipose tissue in both obese and non-obese 
mice,” FEBS Open Bio, vol. 4, pp. 18–24, 2014. 
 
 
 
120 
[12] F. Siebenhaar, F. H. Falcone, E. Tiligada, I. Hammel, M. Maurer, R. Sagi-
Eisenberg, and F. Levi-Schaffer, “The search for mast cell and basophil models - 
Are we getting closer to pathophysiological relevance?,” Allergy Eur. J. Allergy 
Clin. Immunol., vol. 70, no. 1, pp. 1–5, 2015. 
[13] Editorial, “Of men, not mice.,” Nat. Med., vol. 19, p. 379, 2013. 
[14] O. Schmetzer, P. Valentin, M. K. Church, M. Maurer, and F. Siebenhaar, “Murine 
and human mast cell progenitors,” Eur. J. Pharmacol., vol. 778, pp. 2–10, 2016. 
[15] Y. Kitamura, M. Shimada, K. Hatanaka, and Y. Miyano, “Development of mast 
cells from grafted bone marrow cells in irradiated mice,” Nature, vol. 268, no. 
5619, pp. 442–443, 1977. 
[16] A. S. Kirshenbaum, S. W. Kessler, J. P. Goff, and D. D. Metcalfe, “Demonstration 
of the origin of human mast cells from CD34+ bone marrow progenitor cells,” J. 
Immunol., vol. 146, no. 5, pp. 1410–1415, 1991. 
[17] K. Maaninka, J. Lappalainen, and P. T. Kovanen, “Human mast cells arise from a 
common circulating progenitor,” J. Allergy Clin. Immunol., vol. 132, no. 2, p. 463–
469.e3, 2013. 
[18] M. Rottem, T. Okada, J. P. Goff, and D. D. Metcalfe, “Mast cells cultured from the 
peripheral blood of normal donors and patients with mastocytosis originate from a 
CD34+/Fc epsilon RI- cell population.,” Blood, vol. 84, no. 8, pp. 2489–96, 1994. 
[19] J. S. Dahlin, A. Malinovschi, H. Ohrvik, M. Sandelin, C. Janson, K. Alving, and J. 
Hallgren, “Lin- CD34hi CD117 int / hi FceRI+ cells in human blood constitute a 
rare population of mast cell progenitors,” Blood, vol. 127, no. 4, pp. 383–392, 
2016. 
[20] Y. Okayama and T. Kawakami, “Development, migration, and survival of mast 
cells.,” Immunol. Res., vol. 34, no. 2, pp. 97–115, 2006. 
[21] R. Roskoski, “Signaling by Kit protein-tyrosine kinase - The stem cell factor 
receptor,” Biochem. Biophys. Res. Commun., vol. 337, no. 1, pp. 1–13, 2005. 
[22] I. Halova, L. Draberova, and P. Draber, “Mast cell chemotaxis chemoattractants 
and signaling pathways,” Front. Immunol., vol. 3, no. MAY, pp. 1–19, 2012. 
[23] P. Draber, I. Halova, I. Polakovicova, and T. Kawakami, “Signal transduction and 
chemotaxis in mast cells,” Eur. J. Pharmacol., vol. 778, pp. 11–23, 2016. 
[24] J. a Boyce, E. a Mellor, B. Perkins, Y.-C. Lim, and F. W. Luscinskas, “Human 
mast cell progenitors use alpha4-integrin, VCAM-1, and PSGL-1 E-selectin for 
adhesive interactions with human vascular endothelium under flow conditions.,” 
Blood, vol. 99, no. 8, pp. 2890–6, 2002. 
[25] N. P. Azouz, I. Hammel, and R. Sagi-Eisenberg, “Characterization of Mast Cell 
Secretory Granules and Their Cell Biology,” DNA Cell Biol., vol. 33, no. 10, pp. 
647–651, 2014. 
[26] G. J. Molderings, “Mast Cell function in physiology and pathophysiology,” 
Biotrend Rev., vol. 5, no. 1, pp. 1–12, 2010. 
[27] G. H. Caughey, “Mast cell tryptases and chymases in inflammation and host 
defense,” Immunol. Rev., vol. 217, no. 1, pp. 141–154, 2007. 
 
 
121 
[28] C. J. Tifft and R. L. Proia, “The β-hexosaminidase deficiency disorders: 
Development of a clinical paradigm in the mouse,” Ann. Med., vol. 29, no. 6, 
1997. 
[29] M. Jeyakumar, T. D. Butters, R. A. Dwek, and F. M. Platt, “Glycosphingolipid 
lysosomal storage diseases: Therapy and pathogenesis,” Neuropathol. Appl. 
Neurobiol., vol. 28, no. 5, 2002. 
[30] N. Fukuishi, S. Murakami, A. Ohno, N. Yamanaka, N. Matsui, K. Fukutsuji, S. 
Yamada, K. Itoh, and M. Akagi, “Does β-Hexosaminidase Function Only as a 
Degranulation Indicator in Mast Cells? The Primary Role of β-Hexosaminidase in 
Mast Cell Granules,” J. Immunol., vol. 193, no. 4, pp. 1886–1894, 2014. 
[31] L. J. Walsh, G. Trinchieri, H. A. Waldorf, D. Whitaker, G. F. Murphy, L. J. Walsh, 
G. Trinchierit, H. A. Waldorf, D. Whitaker, and G. F. Murphy, “Human Dermal 
Mast Cells Contain and Release Tumor Necrosis Factor α , which Induces 
Endothelial Leukocyte Adhesion Molecule 1 Source : Proceedings of the National 
Academy of Sciences of the United States of America , Published by : National 
Academy of Sci,” 2018. 
[32] M. B. Olszewski, D. Trzaska, E. F. Knol, V. Adamczewska, and J. Dastych, 
“Efficient sorting of TNF-alpha to rodent mast cell granules is dependent on N-
linked glycosylation,” Eur. J. Immunol., vol. 36, no. 4, pp. 997–1008, 2006. 
[33] H. J. Gould and B. J. Sutton, “IgE in allergy and asthma today,” Nat. Rev. 
Immunol., vol. 8, no. 3, pp. 205–217, 2008. 
[34] D. MacGlashan, “IgE receptor and signal transduction in mast cells and 
basophils,” Curr. Opin. Immunol., vol. 20, no. 6, pp. 717–723, 2008. 
[35] S. Kraft and J. P. Kinet, “New developments in FcepsilonRI regulation, function 
and inhibition,” Nat Rev Immunol, vol. 7, no. 5, pp. 365–378, 2007. 
[36] O. Letourneur, S. Sechi, J. Willette-Brown, M. W. Robertson, and J. P. Kinet, 
“Glycosylation of human truncated FcεRI α chain is necessary for efficient folding 
in the endoplasmic reticulum,” Journal of Biological Chemistry, vol. 270, no. 14. 
pp. 8249–8256, 1995. 
[37] J. Kinet, “THE HIGH-AFFINITY I <scp>g</scp> E RECEPTOR (FcεRI): From 
Physiology to Pathology,” Annu. Rev. Immunol., vol. 17, no. 1, pp. 931–972, 1999. 
[38] K. Mukai, M. Tsai, H. Saito, and S. J. Galli, “Mast cells as sources of cytokines, 
chemokines, and growth factors,” Immunol. Rev., vol. 282, no. 1, pp. 121–150, 
Mar. 2018. 
[39] H. Sandig and S. Bulfone-Paus, “TLR signaling in mast cells: common and unique 
features,” Front. Immunol., vol. 3, no. JUL, 2012. 
[40] F. A. Redegeld, Y. Yu, S. Kumari, N. Charles, and U. Blank, “Non-IgE mediated 
mast cell activation,” Immunol. Rev., vol. 282, no. 1, pp. 87–113, 2018. 
[41] K. H. Pinke, H. G. de Lima, F. Q. Cunha, and V. S. Lara, “Mast cells phagocyte 
Candida albicans and produce nitric oxide by mechanisms involving TLR2 and 
Dectin-1,” Immunobiology, vol. 221, no. 2, pp. 220–227, 2016. 
 
 
 
122 
[42] J. C. Hoving, G. J. Wilson, and G. D. Brown, “Signalling C-Type lectin receptors, 
microbial recognition and immunity,” Cell. Microbiol., vol. 16, no. 2, pp. 185–
194, Feb. 2014. 
[43] A. Getahun and J. C. Cambier, “Of ITIMs, ITAMs, and ITAMis: revisiting 
immunoglobulin Fc receptor signaling,” Immunol. Rev., vol. 268, no. 1, pp. 66–73, 
Nov. 2015. 
[44] S. W. Brubaker, K. S. Bonham, I. Zanoni, and J. C. Kagan, “Innate Immune 
Pattern Recognition: A Cell Biological Perspective,” Annu. Rev. Immunol., vol. 33, 
no. 1, pp. 257–290, Mar. 2015. 
[45] M. Chamaillard, S. E. Girardin, J. Viala, and D. J. Philpott, “Nods, nalps and naip: 
Intracellular regulators of bacterial-induced inflammation,” Cell. Microbiol., vol. 
5, no. 9, pp. 581–592, 2003. 
[46] M. Enoksson, K. F. K. Ejendal, S. McAlpine, G. Nilsson, and C. Lunderius-
Andersson, “Human cord blood-derived mast cells are activated by the Nod1 
agonist M-TriDAP to release pro-inflammatory cytokines and chemokines,” J. 
Innate Immun., vol. 3, no. 2, pp. 142–149, 2011. 
[47] H. Subramanian, K. Gupta, and H. Ali, “Roles of Mas-related G protein–coupled 
receptor X2 on mast cell–mediated host defense, pseudoallergic drug reactions, 
and chronic inflammatory diseases,” J. Allergy Clin. Immunol., vol. 138, no. 3, pp. 
700–710, 2016. 
[48] H. Ali, “Regulation of human mast cell and basophil function by anaphylatoxins 
C3a and C5a,” Immunol. Lett., vol. 128, no. 1, pp. 36–45, 2010. 
[49] R. M. Kedzierski and M. Yanagisawa, Endothelin system: The double-edged 
sword in health and disease, vol. 41. 2001. 
[50] M. Maurer, J. Wedemeyer, M. Metz, A. M. Piliponsky, K. Weller, D. Chatterjea, 
D. E. Clouthier, M. M. Yanagisawa, M. Tsai, and S. J. Galli, “Mast cells promote 
homeostasis by limiting endothelin-1-induced toxicity,” Nature, vol. 432, no. 
7016, pp. 512–516, 2004. 
[51] C. Tkaczyk, C. Tkaczyk, Y. Okayama, M. R. Woolhiser, M. R. Woolhiser, D. D. 
Hagaman, D. D. Hagaman, A. M. Gilfillan, A. M. Gilfillan, D. D. Metcalfe, and D. 
D. Metcalfe, “Activation of human mast cells through the high affinity IgG 
receptor,” Mol. Immunol., vol. 38, no. 16–18, pp. 1289–1293, 2002. 
[52] I. D. Lawrence, J. A. Warner, V. L. Cohan, W. C. Hubbard, A. Kagey-Sobotka, 
and L. M. Lichtenstein, “Purification and characterization of human skin mast 
cells. Evidence for human mast cell heterogeneity,” J. Immunol., vol. 139, no. 9, 
pp. 3062–3069, 1987. 
[53] R. C. Benyon, M. A. Lowman, and M. K. Church, “Human skin mast cells: Their 
dispersion, purification, and secretory characterization,” J. Immunol., vol. 138, no. 
3, pp. 861–867, 1987. 
[54] L. B. Schwartz, A.-M. A. Irani, K. Roller, M. C. Castells, and N. M. Schechter, 
“Quantitation of histamine, tryptase, and chymase in dispersed human T and TC 
mast cells,” J. Immunol., vol. 138, no. 8, pp. 2611–2615, 1987. 
 
 
123 
[55] G. Rein and M. A. Karasek, “Factors affecting the growth and maintenance of 
human skin mast cells in cell culture,” Int. Arch. Allergy Immunol., vol. 98, no. 3, 
pp. 211–219, 1992. 
[56] J. Lappalainen, K. A. Lindstedt, and P. T. Kovanen, “A protocol for generating 
high numbers of mature and functional human mast cells from peripheral blood,” 
Clin. Exp. Allergy, vol. 37, no. 9, pp. 1404–1414, 2007. 
[57] O. Schmetzer, P. Valentin, A. Smorodchenko, R. Domenis, G. Gri, F. Siebenhaar, 
M. Metz, and M. Maurer, “A novel method to generate and culture human mast 
cells: Peripheral CD34+ stem cell-derived mast cells (PSCMCs),” J. Immunol. 
Methods, vol. 413, pp. 62–68, 2014. 
[58] I. Y. S. Tam, C. W. Ng, S.-Y. Tam, and H. Y. A. Lau, “Novel six-week protocol 
for generating functional human connective tissue-type (MCTC) mast cells from 
buffy coats,” Inflamm. Res., vol. 66, no. 1, pp. 25–37, 2016. 
[59] T. Furitsu, H. Saito, A. M. Dvorak, L. B. Schwartz, A. A. Irani, J. F. Burdick, K. 
Ishizaka, and T. Ishizaka, “Development of Human Mast Cells in vitro,” Proc. 
Natl. Acad. Sci., vol. 86, no. 24, pp. 10039–10043, 1989. 
[60] D. Kempuraj, H. Saito, A. Kaneko, K. Fukagawa, M. Nakayama, H. Toru, M. 
Tomikawa, H. Tachimoto, M. Ebisawa, A. Akasawa, T. Miyagi, H. Kimura, T. 
Nakajima, K. Tsuji, and T. Nakahata, “Characterization of mast cell-committed 
progenitors present in human umbilical cord blood.,” Blood, vol. 93, no. 10, pp. 
3338–46, 1999. 
[61]  a S. Kirshenbaum, J. P. Goff, S. W. Kessler, J. M. Mican, K. M. Zsebo, and D. D. 
Metcalfe, “Effect of IL-3 and stem cell factor on the appearance of human 
basophils and mast cells from CD34+ pluripotent progenitor cells.,” J. Immunol., 
vol. 148, no. 3, pp. 772–777, 1992. 
[62] A. A. Irani, S. S. Craig, G. Nilsson, T. Ishizaka, and L. B. Schwartz, 
“Characterization of human mast cells developed in vitro from fetal liver cells 
cocultured with murined 3T3 fibroblasts,” Immunology, vol. 77, no. 1, 1992. 
[63] A.-M. A. Irani, G. Nilsson, U. Miettinen, S. S. Craig, L. K. Ashman, T. Ishizaka, 
K. M. Zsebo, and L. B. Schwartz, “Recombinant human stem cell factor stimulates 
differentiation of mast cells from dispersed human fetal liver cells,” Blood, vol. 80, 
no. 12, pp. 3009–3021, 1992. 
[64] F. Ma, N. Kambe, D. Wang, G. Shinoda, H. Fujino, K. Umeda, A. Fujisawa, L. 
Ma, H. Suemori, N. Nakatsuji, Y. Miyachi, R. Torii, K. Tsuji, T. Heike, and T. 
Nakahata, “Direct development of functionally mature tryptase/chymase double-
positive connective tissue-type mast cells from primate embryonic stem cells.,” 
Stem Cells, vol. 26, no. 3, pp. 706–14, 2008. 
[65] M. Kovarova, A. M. Latour, K. D. Chason, S. L. Tilley, and B. H. Koller, “Human 
embryonic stem cells : a source of mast cells for the study of allergic and 
inflammatory diseases,” Differentiation, vol. 115, no. 18, pp. 3695–3703, 2010. 
[66] T. Furitsu, H. Saito, A. M. Dvorak, L. B. Schwartz, A.-M. A. Irani, J. F. Burdick, 
K. Ishizaka, and T. Ishizaka, “Development of human mast cells in vitro,” Proc. 
Natl. Acad. Sci. U. S. A., vol. 86, no. 24, 1989. 
 
124 
[67] H. Gilchrest, B. Cheewatrakoolpong, M. Billah, R. W. Egan, J. C. Anthes, and S. 
Greenfeder, “Human cord blood-derived mast cells synthesize and release I-309 in 
response to IgE,” Life Sci., vol. 73, no. 20, pp. 2571–2581, 2003. 
[68] D.-C. Ding, Y.-H. Chang, W.-C. Shyu, and S.-Z. Lin, “Human umbilical cord 
mesenchymal stem cells: A new era for stem cell therapy,” Cell Transplant., vol. 
24, no. 3, pp. 339–347, 2015. 
[69] N. Cop, I. Decuyper, M. Faber, V. Sabato, C. Bridts, M. Hagendorens, B. De 
Winter, L. De Clerck, and D. Ebo, “Phenotypic and Functional Characterization of 
In Vitro Cultured Human Mast Cells,” Cytom. Part B - Clin. Cytom., vol. 00, no. 
June, p. doi: 10.1002/cyto.b.21399, 2016. 
[70] T. Yoshikubo, T. Inoue, M. Noguchi, and H. Okabe, “Differentiation and 
maintenance of mast cells from CD34+human cord blood cells,” Exp. Hematol., 
vol. 34, no. 3, pp. 320–329, 2006. 
[71] Y. Shimizu, K. Sakai, T. Miura, T. Narita, H. Tsukagoshi, Y. Satoh, S. Ishikawa, 
Y. Morishita, S. Takai, M. Miyazaki, M. Mori, H. Saito, H. Xia, and L. B. 
Schwartz, “Characterization of ‘adult-type’ mast cells derived from human bone 
marrow CD34+cells cultured in the presence of stem cell factor and interleukin-6. 
Interleukin-4 is not required for constitutive expression of CD54, FcεRIα and 
chymase, and CD1,” Clin. Exp. Allergy, vol. 32, no. 6, pp. 872–880, 2002. 
[72] J. H. Butterfield, D. Weiler, G. Dewald, and G. J. Gleich, “Establishment of an 
immature mast cell line from a patient with mast cell leukemia,” Leuk. Res., vol. 
12, no. 4, pp. 345–355, 1988. 
[73] Y. Kanakura, T. Furitsu, T. Tsujimura, J. H. Butterfield, L. K. Ashman, H. Ikeda, 
H. Kitayama, Y. Kanayama, Y. Matsuzawa, and Y. Kitamura, “Activating 
mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line,” 
Leukemia, vol. 8, no. SUPPL.1, 1994. 
[74] K. S. Love, R. R. Lakshmanan, J. H. Butterfield, and C. C. Fox, “IFN-γ-stimulated 
enhancement of MHC class II antigen expression by the human mast cell line 
HMC-1,” Cell. Immunol., vol. 170, no. 1, pp. 85–90, 1996. 
[75] G. NILSSON, T. BLOM, M. KUSCHE-GULLBERG, L. KJELLEN, J. H. 
BUTTERFIELD, C. SUNDSTRÖM, K. NILSSON, and L. HELLMAN, 
“Phenotypic Characterization of the Human Mast-Cell Line HMC-1,” Scand. J. 
Immunol., vol. 39, no. 5, pp. 489–498, 1994. 
[76] A. S. Kirshenbaum, C. Akin, Y. Wu, M. Rottem, J. P. Goff, M. A. Beaven, V. K. 
Rao, and D. D. Metcalfe, “Characterization of novel stem cell factor responsive 
human mast cell lines LAD 1 and 2 established from a patient with mast cell 
sarcoma/leukemia; Activation following aggregation of FcεRI or FcγRI,” Leuk. 
Res., vol. 27, no. 8, 2003. 
[77] S. Guhl, M. Babina, A. Neou, T. Zuberbier, and M. Artuc, “Mast cell lines HMC-1 
and LAD2 in comparison with mature human skin mast cells - drastically reduced 
levels of tryptase and chymase in mast cell lines,” Exp. Dermatol., vol. 19, no. 9, 
pp. 845–847, 2010. 
 
 
125 
[78] T. M. Laidlaw, J. W. Steinke, A. M. Tiñana, C. Feng, W. Xing, B. K. Lam, S. 
Paruchuri, J. A. Boyce, and L. Borish, “Characterization of a novel human mast 
cell line that responds to stem cell factor and expresses functional FcεRI,” J. 
Allergy Clin. Immunol., vol. 127, no. 3, pp. 815–822, 2011. 
[79] A. S. Kirshenbaum, R. Walsh, L. Kirby, S. Vepa, T. Ried, and D. Metcalfe, “A 
Ten-Year Retrospective Analysis of the Distribution , Use and Phenotypic 
Characteristics of the LAD2 Human Mast Cell Line,” vol. 1881, pp. 265–270, 
2014. 
[80] Y. Kitamura, S. Go, and K. Hatanaka, “Decrease of mast cells in W/W(V) mice 
and their increase by bone marrow transplantation,” Blood, vol. 52, no. 2, pp. 447–
452, 1978. 
[81] M. Maurer and M. Metz, “The status quo and quo vadis of mast cells,” Exp. 
Dermatol., vol. 14, no. 12, pp. 923–929, 2005. 
[82] H. M. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, 
Lorenz HP, “Multilineage cells from human adipose tissue: implications for cell-
based therapies.,” Tissue Eng., vol. 7, no. 2, pp. 211–228, 2001. 
[83] A. I. Caplan, “Mesenchymal stem cells,” J. Orthop. Res., vol. 9, no. 5, pp. 641–
650, 1991. 
[84] M. F. Pittenger, A. M. Mackay, S. C. Beck, R. K. Jaiswal, R. Douglas, J. D. 
Mosca, M. A. Moorman, D. W. Simonetti, S. Craig, and D. R. Marshak, 
“Multilineage potential of adult human mesenchymal stem cells,” Science (80-. )., 
vol. 284, no. 5411, pp. 143–147, 1999. 
[85] S. Wakitani, T. Saito, and A. I. Caplan, “Myogenic cells derived from rat bone 
marrow mesenchymal stem cells exposed to 5-azacytidine,” Muscle Nerve, vol. 18, 
no. 12, pp. 1417–1426, 1995. 
[86] D. J. Warejcka, R. Harvey, B. J. Taylor, H. E. Young, and P. A. Lucas, “A 
population of cells isolated from rat heart capable of differentiating into several 
mesodermal phenotypes,” J. Surg. Res., vol. 62, no. 2, pp. 233–242, 1996. 
[87] H. E. Young, E. M. Ceballos, J. C. Smith, P. A. Lucas, and D. C. Morrison, 
“Isolation of embryonic chick myosatellite and pluripotent stem cells,” J. Tissue 
Cult. Methods, vol. 14, no. 2, pp. 85–92, 1992. 
[88] G. Löffler and H. Hauner, “Adipose tissue development: The role of precursor 
cells and adipogenic factors - Part II: The regulation of the adipogenic conversion 
by hormones and serum factors,” Klin. Wochenschr., vol. 65, no. 17, pp. 812–817, 
1987. 
[89] M. RODBELL, “METABOLISM OF ISOLATED FAT CELLS. I. EFFECTS OF 
HORMONES ON GLUCOSE,” J. Biol. Chem., vol. 239, 1964. 
[90] C. H. Hollenberg and A. Vost, “Regulation of DNA synthesis in fat cells and 
stromal elements from rat adipose tissue.,” J. Clin. Invest., vol. 47, no. 11, pp. 
2485–98, 1969. 
[91] R. L. R. Van, C. E. Bayliss, and D. A. K. Roncari, “Cytological and enzymological 
characterization of adult human adipocyte precursors in culture,” J. Clin. Invest., 
vol. 58, no. 3, pp. 699–704, 1976. 
 
126 
[92] H. Hauner, P. Schmid, and E. F. Pfeiffer, “Glucocorticoids and insulin promote the 
differentiation of human adipocyte precursor cells into fat cells,” J. Clin. 
Endocrinol. Metab., vol. 64, no. 4, pp. 832–835, 1987. 
[93] M. Dhanasekaran, S. Indumathi, A. Kanmani, R. Poojitha, K. M. Revathy, J. S. 
Rajkumar, and D. Sudarsanam, “Surface antigenic profiling of stem cells from 
human omentum fat in comparison with subcutaneous fat and bone marrow,” 
Cytotechnology, vol. 64, no. 5, pp. 497–509, 2012. 
[94] K. Yoshimura, T. Shigeura, D. Matsumoto, T. Sato, Y. Takaki, E. Aiba-Kojima, 
K. Sato, K. Inoue, T. Nagase, I. Koshima, and K. Gonda, “Characterization of 
freshly isolated and cultured cells derived from the fatty and fluid portions of 
liposuction aspirates,” J. Cell. Physiol., vol. 208, no. 1, pp. 64–76, 2006. 
[95] W. J. F. M. Jurgens, M. J. Oedayrajsingh-Varma, M. N. Helder, B. 
ZandiehDoulabi, T. E. Schouten, D. J. Kuik, M. J. P. F. Ritt, and F. J. Van 
Milligen, “Effect of tissue-harvesting site on yield of stem cells derived from 
adipose tissue: Implications for cell-based therapies,” Cell Tissue Res., vol. 332, 
no. 3, pp. 415–426, 2008. 
[96] E. Luche, C. Sengen??s, E. Arnaud, P. Laharrague, L. Casteilla, and B. Cousin, 
“Differential Hematopoietic Activity in White Adipose Tissue Depending on its 
Localization,” J. Cell. Physiol., vol. 230, no. 12, pp. 3076–3083, 2015. 
[97] A. Bajek, N. Gurtowska, J. Olkowska, M. Maj, Ł. Kaźmierski, M. Bodnar, A. 
Marszałek, R. Dębski, and T. Drewa, “Does the Harvesting Technique Affect the 
Properties of Adipose-Derived Stem Cells? - The Comparative Biological 
Characterization,” J. Cell. Biochem., vol. 11, no. June, pp. 1–11, 2016. 
[98] T. Yi, W.-K. Kim, J.-S. Choi, S. Y. Song, J. Han, J. H. Kim, W.-S. Kim, S. G. 
Park, H.-J. Lee, Y. K. Cho, S.-J. Hwang, S. U. Song, and J.-H. Sung, “Isolation of 
adipose-derived stem cells by using a subfractionation culturing method,” Expert 
Opin. Biol. Ther., vol. 14, no. 11, pp. 1551–1560, 2014. 
[99] N. Priya, S. Sarcar, A. Sen Majumdar, and S. Sundarraj, “Explant culture: A 
simple, reproducible, efficient and economic technique for isolation of 
mesenchymal stromal cells from human adipose tissue and lipoaspirate,” J. Tissue 
Eng. Regen. Med., vol. 8, no. 9, pp. 706–716, 2014. 
[100] R. W. Alexander, “Understanding Mechanical Emulsification ( Nanofat ) Versus 
Enzymatic Isolation of Tissue Stromal Vascular Fraction ( tSVF ) Cells from 
Adipose Tissue : Potential Uses in Biocellular Regenerative Medicine,” J. 
Prolotherapy, vol. 8, pp. 947–960, 2016. 
[101] C. A. Kemaloğlu, “Nanofat grafting under a split-thickness skin graft for 
problematic wound management.,” Springerplus, vol. 5, no. 1, p. 138, 2016. 
[102] M. A. Shiffman and S. Mirrafati, “Fat transfer techniques: The effect of harvest 
and transfer methods on adipocyte viability and review of the literature,” 
Dermatologic Surg., vol. 27, no. 9, pp. 819–826, 2001. 
[103] P. Tonnard, A. Verpaele, G. Peeters, M. Hamdi, M. Cornelissen, and H. Declercq, 
“Nanofat Grafting - Basic Research and Clinical Applications,” Plast. Reconstr. 
Surg., vol. 132, no. 4, pp. 1017–1026, 2013. 
 
127 
[104] C.-H. Wu, F.-K. Lee, S. Suresh Kumar, Q.-D. Ling, Y. Chang, Y. Chang, H.-C. 
Wang, H. Chen, D.-C. Chen, S.-T. Hsu, and A. Higuchi, “The isolation and 
differentiation of human adipose-derived stem cells using membrane filtration,” 
Biomaterials, vol. 33, no. 33, pp. 8228–8239, 2012. 
[105] A. Higuchi, C.-T. Wang, Q.-D. Ling, H. H.-C. Lee, S. S. Kumar, Y. Chang, A. A. 
Alarfaj, M. A. Munusamy, S.-T. Hsu, G.-J. Wu, and A. Umezawa, “A hybrid-
membrane migration method to isolate high-purity adipose-derived stem cells from 
fat tissues,” Sci. Rep., vol. 5, 2015. 
[106] H. R. Lin, C.-W. Heish, C.-H. Liu, S. Muduli, H.-F. Li, A. Higuchi, S. S. Kumar, 
A. A. Alarfaj, M. A. Munusamy, S.-T. Hsu, D.-C. Chen, G. Benelli, K. Murugan, 
N.-C. Cheng, H.-C. Wang, and G.-J. Wu, “Purification and differentiation of 
human adipose-derived stem cells by membrane filtration and membrane 
migration methods,” Sci. Rep., vol. 7, no. January, p. 40069, 2017. 
[107] G. Yang, Z. Xiao, X. Ren, H. Long, K. Ma, H. Qian, and Y. Guo, “Obtaining 
spontaneously beating cardiomyocyte-like cells from adipose-derived stromal 
vascular fractions cultured on enzyme-crosslinked gelatin hydrogels,” Sci. Rep., 
vol. 7, no. December 2016, p. 41781, 2017. 
[108] H. Salehi, N. Amirpour, A. Niapour, and S. Razavi, “An Overview of Neural 
Differentiation Potential of Human Adipose Derived Stem Cells,” Stem Cell Rev. 
Reports, pp. 1–16, 2015. 
[109] V. Planat-Benard, “Plasticity of Human Adipose Lineage Cells Toward 
Endothelial Cells: Physiological and Therapeutic Perspectives,” Circulation, vol. 
109, no. 5, pp. 656–663, 2004. 
[110] M. Brzoska, H. Geiger, S. Gauer, and P. Baer, “Epithelial differentiation of human 
adipose tissue-derived adult stem cells,” Biochem. Biophys. Res. Commun., vol. 
330, no. 1, 2005. 
[111] H. Ning, G. Liu, G. Lin, R. Yang, T. F. Lue, and C.-S. Lin, “Fibroblast growth 
factor 2 promotes endothelial differentiation of adipose tissue-derived stem cell,” 
J. Sex. Med., vol. 6, no. 4, pp. 967–979, 2009. 
[112] K. M. Safford, K. C. Hicok, S. D. Safford, Y.-D. C. Halvorsen, W. O. Wilkison, J. 
M. Gimble, and H. E. Rice, “Neurogenic differentiation of murine and human 
adipose-derived stromal cells,” Biochem. Biophys. Res. Commun., vol. 294, no. 2, 
pp. 371–379, 2002. 
[113] Y. S. Choi, G. J. Dusting, S. Stubbs, S. Arunothayaraj, X. L. Han, P. Collas, W. A. 
Morrison, and R. J. Dilley, “Differentiation of human adipose-derived stem cells 
into beating cardiomyocytes,” J. Cell. Mol. Med., vol. 14, no. 4, pp. 878–889, 
2010. 
[114] P. A. Zuk, M. Zhu, P. Ashjian, D. A. De Ugarte, J. I. Huang, H. Mizuno, Z. C. 
Alfonso, J. K. Fraser, P. Benhaim, and M. H. Hedrick, “Human adipose tissue is a 
source of multipotent stem cells,” Mol. Biol. Cell, vol. 13, no. 12, pp. 4279–4295, 
2002. 
 
 
 
128 
[115] J. M. Gimble, B. A. Bunnell, E. S. Chiu, and F. Guilak, “Concise review: Adipose-
derived stromal vascular fraction cells and stem cells: Let’s not get lost in 
translation,” Stem Cells, vol. 29, no. 5, pp. 749–754, 2011. 
[116] P. Bourin, B. A. Bunnell, L. Casteilla, M. Dominici, A. J. Katz, K. L. March, H. 
Redl, J. P. Rubin, K. Yoshimura, and J. M. Gimble, “Stromal cells from the 
adipose tissue-derived stromal vascular fraction and culture expanded adipose 
tissue-derived stromal/ stem cells: a joint statement of the International Federation 
for Adipose Therapeutics (IFATS) and Science and the International S,” 
Cytotherapy, vol. 15, no. 6, pp. 641–648, 2013. 
[117] F. S. Shah, J. Li, M. Dietrich, X. Wu, M. G. Hausmann, K. A. Leblanc, J. W. 
Wade, and J. M. Gimble, “Comparison of stromal/stem cells isolated from human 
omental and subcutaneous adipose depots: Differentiation and immunophenotypic 
characterization,” Cells Tissues Organs, vol. 200, pp. 204–211, 2015. 
[118] L. Oravcova, M. Bohac, L. Krajciova, S. Polak, D. Bohmer, and L. Danisovic, 
“Effect of Serial Passaging on the Morphology and Biological Characteristics of 
Human Adipose Tissue-derived Stem Cells,” Online J. Biol. Sci., 2016. 
[119] Y. Bian, C. Deng, W. Li, Z. Lei, Y. Li, and X. Li, “A comparative study on the 
biological characteristics of human adipose-derived stem cells from lipectomy and 
liposuction,” PLoS One, vol. 11, no. 9, pp. 1–17, 2016. 
[120] L. H. Mangum, S. Natesan, R. Stone, N. L. Wrice, D. A. Larson, K. F. Florell, B. 
A. Christy, M. C. Herzig, A. P. Cap, and R. J. Christy, “Tissue Source and Cell 
Expansion Condition Influence Phenotypic Changes of Adipose-Derived Stem 
Cells,” Stem Cells Int., vol. 2017, 2017. 
[121] J. M. Gimble and F. Guilak, “Adipose-derived adult stem cells: Isolation, 
characterization, and differentiation potential,” Cytotherapy, vol. 5, no. 5, 2003. 
[122] J. M. Gimble and F. Guilak, Differentiation Potential of Adipose Derived Adult 
Stem (ADAS) Cells, vol. 58. 2003. 
[123] A. Dicker, K. Le Blanc, G. Åström, V. Van Harmelen, C. Götherström, L. 
Blomqvist, P. Arner, and M. Rydén, “Functional studies of mesenchymal stem 
cells derived from adult human adipose tissue,” Exp. Cell Res., vol. 308, no. 2, pp. 
283–290, 2005. 
[124] B. M. Strem, K. C. Hicok, M. Zhu, I. Wulur, Z. Alfonso, R. E. Schreiber, J. K. 
Fraser, and M. H. Hedrick, “Multipotential differentiation of adipose tissue-
derived stem cells,” Keio J. Med., vol. 54, no. 0022–9717 (Print), pp. 132–141, 
2005. 
[125] M. J. O. Varma, R. G. M. Breuls, T. E. Schouten, W. J. F. M. Jurgens, H. J. 
Bontkes, G. J. Schuurhuis, S. M. van Ham, and F. J. van Milligen, “Phenotypical 
and functional characterization of freshly isolated adipose tissue-derived stem 
cells.,” Stem Cells Dev., vol. 16, no. 1, pp. 91–104, 2007. 
[126] M. Locke, J. Windsor, and P. R. Dunbar, “Human adipose-derived stem cells: 
Isolation, characterization and applications in surgery,” ANZ J. Surg., vol. 79, no. 
4, pp. 235–244, 2009. 
 
 
129 
[127] H. Suga, D. Matsumoto, H. Eto, K. Inoue, N. Aoi, H. Kato, J. Araki, and K. 
Yoshimura, “Functional Implications of CD34 Expression in Human Adipose–
Derived Stem/Progenitor Cells,” Stem Cells Dev., vol. 18, no. 8, pp. 1201–1210, 
2009. 
[128] L. Zimmerlin, V. S. Donnenberg, M. E. Pfeifer, E. M. Meyer, B. Péault, J. P. 
Rubin, and A. D. Donnenberg, “Stromal vascular progenitors in adult human 
adipose tissue,” Cytom. Part A, vol. 77, no. 1, pp. 22–30, 2010. 
[129] U.S. Cancer Statistics Working Group, “United States Cancer Statistics.” [Online]. 
Available: https://nccd.cdc.gov/uscs/toptencancers.aspx. [Accessed: 10-May-
2018]. 
[130] C. M. Perou, T. Sørile, M. B. Eisen, M. Van De Rijn, S. S. Jeffrey, C. A. Ress, J. 
R. Pollack, D. T. Ross, H. Johnsen, L. A. Akslen, Ø. Fluge, A. 
Pergammenschlkov, C. Williams, S. X. Zhu, P. E. Lønning, A.-L. Børresen-Dale, 
P. O. Brown, and D. Botstein, “Molecular portraits of human breast tumours,” 
Nature, vol. 406, no. 6797, pp. 747–752, 2000. 
[131] J. R. Pollack, C. M. Perou, A. A. Alizadeh, M. B. Eisen, A. Pergamenschikov, C. 
F. Williams, S. S. Jeffrey, D. Botstein, and P. O. Brown, “Genome-wide analysis 
of DNA copy-number changes using cDNA microarrays,” Nat. Genet., vol. 23, no. 
1, pp. 41–46, 1999. 
[132] G. Pauletti, W. Godolphin, M. F. Press, and D. J. Slamon, “Detection and 
quantitation of HER-2/neu gene amplification in human breast cancer archival 
material using fluorescence in situ hybridization,” Oncogene, vol. 13, no. 1, pp. 
63–72, 1996. 
[133] W. D. Foulkes, I. E. Smith, and J. S. Reis-Filho, “Triple-negative breast cancer,” 
N. Engl. J. Med., vol. 363, no. 20, pp. 1938–1948, 2010. 
[134] C. L. Arteaga and J. A. Engelman, “ERBB receptors: From oncogene discovery to 
basic science to mechanism-based cancer therapeutics,” Cancer Cell, vol. 25, no. 
3, pp. 282–303, 2014. 
[135] J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. 
Hortobagyi, “The HER-2 Receptor and Breast Cancer: Ten Years of Targeted 
Anti-HER-2 Therapy and Personalized Medicine,” Oncologist, vol. 14, no. 4, pp. 
320–368, 2009. 
[136] N. E. Hynes and H. a Lane, “ERBB receptors and cancer: the complexity of 
targeted inhibitors.,” Nat. Rev. Cancer, vol. 5, no. 5, pp. 341–54, 2005. 
[137] V. P. Ramsauer, C. A. . Carraway, P. J. I. Salas, and K. L. Carraway, 
“Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 
to the apical surface in polarized epithelial cells,” J. Biol. Chem., vol. 278, no. 32, 
pp. 30142–30147, 2003. 
[138] D. Graus-Porta, R. R. Beerli, J. M. Daly, and N. E. Hynes, “ErbB-2, the preferred 
heterodimerization partner of all ErbB receptors, is a mediator of lateral 
signaling,” EMBO J., vol. 16, no. 7, pp. 1647–1655, 1997. 
 
 
 
130 
[139] A. Gschwind, O. M. Fischer, and A. Ullrich, “The discovery of receptor tyrosine 
kinases: Targets for cancer therapy,” Nat. Rev. Cancer, vol. 4, no. 5, pp. 361–370, 
2004. 
[140] P. Sunpaweravong, S. Sunpaweravong, P. Puttawibul, W. Mitarnun, C. Zeng, A. 
E. Barón, W. Franklin, S. Said, and M. Varella-Garcia, “Epidermal growth factor 
receptor and cyclin D1 are independently amplified and overexpressed in 
esophageal squamous cell carcinoma,” J. Cancer Res. Clin. Oncol., vol. 131, no. 2, 
pp. 111–119, 2005. 
[141] D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. 
McGuire, “Human breast cancer: Correlation of relapse and survival with 
amplification of the HER-2/neu oncogene,” Science (80-. )., vol. 235, no. 4785, pp. 
177–182, 1987. 
[142] D. S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno, “Epidermal growth 
factor-related peptides and their receptors in human malignancies,” Crit. Rev. 
Oncol. Hematol., vol. 19, no. 3, pp. 183–232, 1995. 
[143] L. Yen, N. Benlimame, Z.-R. Nie, D. Xiao, T. Wang, A.-E. Al Moustafa, H. 
Esumi, J. Milanini, N. E. Hynes, G. Pages, and M. A. Alaoui-Jamali, “Differential 
regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers,” Mol. 
Biol. Cell, vol. 13, no. 11, pp. 4029–4044, 2002. 
[144] M. Campillo-Navarro, A. D. Chávez-Blanco, I. Wong-Baeza, J. Serafín-López, R. 
Flores-Mejía, S. Estrada-Parra, I. Estrada-García, and R. Chacón-Salinas, “Mast 
Cells in Lung Homeostasis: Beyond Type I Hypersensitivity.,” Curr. Respir. Med. 
Rev., vol. 10, no. 2, pp. 115–123, 2014. 
[145] D. Ribatti, “Mast cells in lymphomas,” Crit. Rev. Oncol. Hematol., vol. 101, pp. 
207–212, 2016. 
[146] S. Aaltomaa, P. Lipponen, S. Papinaho, and V.-M. Kosma, “Mast cells in breast 
cancer,” Anticancer Res., vol. 13, no. 3, pp. 785–788, 1993. 
[147] D. Ribatti and E. Crivellato, Mast cells, angiogenesis and cancer, vol. 716. 2011. 
[148] F. D. Finkelman, “Anaphylaxis: Lessons from mouse models,” J. Allergy Clin. 
Immunol., vol. 120, no. 3, pp. 506–515, 2007. 
[149] M. M. Epstein, “Do Mouse Models of Allergic Asthma Mimic Clinical Disease?,” 
Int. Arch. Allergy Immunol., vol. 133, no. 1, pp. 84–100, 2004. 
[150] J. Mestas and C. C. W. Hughes, “Of Mice and Not Men: Differences between 
Mouse and Human Immunology,” J. Immunol., vol. 172, no. 5, pp. 2731–2738, 
2004. 
[151] M. J. Sinnamon, K. J. Carter, L. P. Sims, B. Lafleur, B. Fingleton, and L. M. 
Matrisian, “A protective role of mast cells in intestinal tumorigenesis,” 
Carcinogenesis, vol. 29, no. 4, pp. 880–886, 2008. 
[152] A. Johansson, S. Rudolfsson, P. Hammarsten, S. Halin, K. Pietras, J. Jones, P. 
Stattin, L. Egevad, T. Granfors, P. Wikström, and A. Bergh, “Mast cells are novel 
independent prognostic markers in prostate cancer and represent a target for 
therapy.,” Am. J. Pathol., vol. 177, no. 2, pp. 1031–41, 2010. 
 
 
131 
[153] B. F. Gibbs, J. Wierecky, P. Welker, B. M. Henz, H. H. Wolff, and J. Grabbe, 
“Human skin mast cells rapidly release preformed and newly generated TNF-α and 
IL-8 following stimulation with anti-IgE and other secretagogues,” Exp. 
Dermatol., vol. 10, no. 5, pp. 312–320, 2001. 
[154] J. R. Gordon and S. J. Galli, “Mast cells as a source of both preformed and 
immunologically inducible TNF-α/cachectin,” Nature, vol. 346, no. 6281, pp. 
274–276, 1990. 
[155] A. L. Dellinger, P. Cunin, D. Lee, A. L. Kung, D. B. Brooks, Z. Zhou, P. A. 
Nigrovic, and C. L. Kepley, “Inhibition of inflammatory arthritis using fullerene 
nanomaterials,” PLoS One, vol. 10, no. 4, 2015. 
[156] S. K. Norton, A. Dellinger, Z. Zhou, R. Lenk, D. MacFarland, B. Vonakis, D. 
Conrad, and C. L. Kepley, “A new class of human mast cell and peripheral blood 
basophil stabilizers that differentially control allergic mediator release,” Clin. 
Transl. Sci., vol. 3, no. 4, pp. 158–169, 2010. 
[157] S. Green, “Murine tumor necrosis-inducing factor: Purification and effects on 
myelomonocytic leukemia cells,” J. Natl. Cancer Inst., vol. 68, no. 6, pp. 997–
1003, 1982. 
[158] X. Wang and Y. Lin, “Tumor necrosis factor and cancer, buddies or foes?,” Acta 
Pharmacol. Sin., vol. 29, no. 11, pp. 1275–1288, 2008. 
[159] D. J. Grünhagen, J. H. W. de Wilt, T. L. M. ten Hagen, and A. M. M. Eggermont, 
“Technology insight: Utility of TNF-α-based isolated limb perfusion to avoid 
amputation of irresectable tumors of the extremities,” Nat. Clin. Pract. Oncol., vol. 
3, no. 2, pp. 94–103, 2006. 
[160] T. E. Lans, D. J. Grünhagen, J. H. W. De Wilt, A. N. Van Geel, and A. M. M. 
Eggermont, “Isolated limb perfusions with tumor necrosis factor and melphalan 
for locally recurrent soft tissue sarcoma in previously irradiated limbs,” Ann. Surg. 
Oncol., vol. 12, no. 5, pp. 1–6, 2005. 
[161] A. J. Hayes, S. J. Neuhaus, M. A. Clark, and J. M. Thomas, “Isolated limb 
perfusion with melphalan and tumor necrosis factor α for advanced melanoma and 
soft-tissue sarcoma,” Ann. Surg. Oncol., vol. 14, no. 1, pp. 230–238, 2007. 
[162] F. Di Filippo, R. Garinei, M. Anzà, F. Cavaliere, D. Giannarelli, P. P. Cagol, C. R. 
Rossi, M. Santinami, M. Deraco, C. Botti, P. Perri, S. Di Filippo, L. Piarulli, and 
P. Bruno, “Doxorubicin in Isolation Limb Perfusion in the Treatment of Advanced 
Limb Soft Tissue Sarcoma,” J. Exp. Clin. Cancer Res., vol. 22, no. 4 SUPPL., pp. 
81–87, 2003. 
[163] C. R. Rossi, S. Mocellin, P. Pilati, M. Foletto, L. Campana, L. Quintieri, G. L. De 
Salvo, and M. Lise, “Hyperthermic isolated perfusion with low-dose tumor 
necrosis factor α and doxorubicin for the treatment of limb-threatening soft tissue 
sarcomas,” Ann. Surg. Oncol., vol. 12, no. 5, pp. 1–8, 2005. 
[164] T. D. Eubank, R. D. Roberts, M. Khan, J. M. Curry, G. J. Nuovo, P. Kuppusamy, 
and C. B. Marsh, “Granulocyte macrophage colony-stimulating factor inhibits 
breast cancer growth and metastasis by invoking an anti-angiogenic program in 
tumor-educated macrophages,” Cancer Res., vol. 69, no. 5, pp. 2133–2140, 2009. 
 
132 
[165] Y. C. Cheng, V. Valero, M. L. Davis, M. C. Green, A. M. Gonzalez-Angulo, R. L. 
Theriault, J. L. Murray, G. N. Hortobagyi, and N. T. Ueno, “Addition of GM-CSF 
to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast 
cancer patients,” Br. J. Cancer, vol. 103, no. 9, pp. 1331–1334, 2010. 
[166] R. A. Prell, L. Gearin, A. Simmons, M. VanRoey, and K. Jooss, “The anti-tumor 
efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel 
administration,” Cancer Immunol. Immunother., vol. 55, no. 10, pp. 1285–1293, 
2006. 
[167] G. T. Clifton, V. Gall, G. E. Peoples, and E. A. Mittendorf, “Clinical Development 
of the E75 Vaccine in Breast Cancer,” Breast Care, vol. 11, no. 2, pp. 116–121, 
2016. 
[168] N. Molomut, D. M. Spain, L. Kreisler, and L. J. Warshaw, “The Effect of an 
Allergic Inflammatory Response in the Tumor Bed on the Fate of Transplanted 
Tumors in Mice,” Cancer Res., vol. 15, no. 3, pp. 181–183, 1955. 
[169] J. Allegra, A. Lipton, H. Harvey, J. Luderer, D. Brenner, R. Mortel, L. Demers, M. 
Gillin, D. White, and J. Trautlein, “Decreased prevalence of immediate 
hypersensitivity (atopy) in a cancer population,” Cancer Res., vol. 36, no. 9, 1976. 
[170] C. Burtin, C. Noirot, J. Paupe, and P. Scheinmann, “Decreased blood histamine 
levels in patients with solid malignant tumours,” Br. J. Cancer, vol. 47, no. 3, pp. 
367–372, 1983. 
[171] C. Burtin, C. Noirot, C. Giroux, and P. Scheinmann, “Decreased skin response to 
intradermal histamine in cancer patients,” J. Allergy Clin. Immunol., vol. 78, no. 1 
PART 1, pp. 83–89, 1986. 
[172] L. Galoppin, C. Noirot, J. P. Wastiaux, P. Scheinmann, J. Paupe, and C. Burtin, 
“Comparison between number of basophils, blood histamine, and histamine 
release in cancer and noncancer patients,” J. Allergy Clin. Immunol., vol. 84, no. 4 
PART 1, pp. 501–506, 1989. 
[173] M. C. Turner, Y. Chen, D. Krewski, P. Ghadirian, M. J. Thun, and E. E. Calle, 
“Cancer mortality among US men and women with asthma and hay fever,” Am. J. 
Epidemiol., vol. 162, no. 3, pp. 212–221, 2005. 
[174] M. Bracher, H. J. Gould, B. J. Sutton, D. Dombrowicz, and S. N. Karagiannis, 
“Three-colour flow cytometric method to measure antibody-dependent tumour cell 
killing by cytotoxicity and phagocytosis,” J. Immunol. Methods, vol. 323, no. 2, 
pp. 160–171, 2007. 
[175] E. Jensen-Jarolim, G. Achatz, M. C. Turner, S. Karagiannis, F. Legrand, M. 
Capron, M. L. Penichet, J. A. Rodríguez, A. G. Siccardi, L. Vangelista, A. B. 
Riemer, and H. Gould, “AllergoOncology: The role of IgE-mediated allergy in 
cancer,” Allergy Eur. J. Allergy Clin. Immunol., vol. 63, no. 10, pp. 1255–1266, 
2008. 
[176] T. A. Waldmann, A. Iio, M. Ogawa, O. R. McIntyre, and W. Strober, “The 
metabolism of IgE. Studies in normal individuals and in a patient with IgE 
myeloma,” J. Immunol., vol. 117, no. 4, pp. 1139–1144, 1976. 
 
 
133 
[177] P. Vieira and K. Rajewsky, “The half-lives of serum immunoglobulins in adult 
mice,” Eur. J. Immunol., vol. 18, no. 2, pp. 313–316, 1988. 
[178] H. J. Gould, G. A. Mackay, S. N. Karagiannis, C. M. O’Toole, P. J. Marsh, B. E. 
Daniel, L. R. Coney, V. R. Zurawski Jr., M. Joseph, M. Capron, M. Gilbert, G. F. 
Murphy, and R. Korngold, “Comparison of IgE and IgG antibody-dependent 
cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma,” 
Eur. J. Immunol., vol. 29, no. 11, pp. 3527–3537, 1999. 
[179] L. R. Coney, D. Sanborn, and V. R. Zurawski, “Chimeric Murine-Human 
Antibodies Directed against Folate Binding Receptor Are Efficient Mediators of 
Ovarian Carcinoma Cell Killing,” Cancer Res., vol. 54, no. 9, pp. 2448–2455, 
1994. 
[180] S. N. Karagiannis, Q. Wang, N. East, F. Burke, S. Riffard, M. G. Bracher, R. G. 
Thompson, S. R. Durham, L. B, F. R. Balkwill, and H. J. Gould, “Activity of 
human monocytes in IgE antibody- dependent surveillance and killing of ovarian 
tumor cells,” Hear. Lung, pp. 1030–1040, 2003. 
[181] S. N. Karagiannis, M. G. Bracher, J. Hunt, N. McCloskey, R. L. Beavil, A. J. 
Beavil, D. J. Fear, R. G. Thompson, N. East, F. Burke, R. J. Moore, D. D. 
Dombrowicz, F. R. Balkwill, and H. J. Gould, “IgE-Antibody-Dependent 
Immunotherapy of Solid Tumors: Cytotoxic and Phagocytic Mechanisms of 
Eradication of Ovarian Cancer Cells,” J. Immunol., vol. 179, no. 5, pp. 2832–2843, 
2007. 
[182] A. B. Riemer, M. Klinger, S. Wagner, A. Bernhaus, L. Mazzucchelli, H. 
Pehamberger, O. Scheiner, C. C. Zielinski, and E. Jensen-Jarolim, “Generation of 
peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein 
Her-2/neu,” J. Immunol., vol. 173, no. 1, pp. 394–401, 2004. 
[183] A. B. Riemer, E. Untersmayr, R. Knittelfelder, A. Duschl, H. Pehamberger, C. C. 
Zielinski, O. Scheiner, and E. Jensen-Jarolim, “Active induction of tumor-specific 
IgE antibodies by oral mimotope vaccination,” Cancer Res., vol. 67, no. 7, pp. 
3406–3411, 2007. 
[184] P. Karagiannis, J. Singer, J. Hunt, S. K. E. Gan, S. M. Rudman, D. 
Mechtcheriakova, R. Knittelfelder, T. R. Daniels, P. S. Hobson, A. J. Beavil, J. 
Spicer, F. O. Nestle, M. L. Penichet, H. J. Gould, E. Jensen-Jarolim, and S. N. 
Karagiannis, “Characterisation of an engineered trastuzumab IgE antibody and 
effector cell mechanisms targeting HER2/neu-positive tumour cells,” Cancer 
Immunol. Immunother., vol. 58, no. 6, pp. 915–930, 2009. 
[185] T. R. Daniels, R. K. Leuchter, R. Quintero, G. Helguera, J. A. Rodríguez, O. 
Martínez-Maza, B. C. Schultes, C. F. Nicodemus, and M. L. Penichet, “Targeting 
HER2/neu with a fully human IgE to harness the allergic reaction against cancer 
cells,” Cancer Immunol. Immunother., vol. 61, no. 7, pp. 991–1003, 2012. 
[186] J. D. Plotkin, M. G. Elias, A. L. Dellinger, and C. L. Kepley, “NF-κB inhibitors 
that prevent foam cell formation and atherosclerotic plaque accumulation,” 
Nanomedicine Nanotechnology, Biol. Med., vol. 13, no. 6, 2017. 
 
 
134 
[187] G. Bonuccelli, E. M. De Francesco, R. de Boer, H. B. Tanowitz, M. P. Lisanti, G. 
Bonuccelli, E. M. De Francesco, R. de Boer, H. B. Tanowitz, and M. P. Lisanti, 
“NADH autofluorescence, a new metabolic biomarker for cancer stem cells: 
Identification of Vitamin C and CAPE as natural products targeting ‘stemness,’” 
Oncotarget, vol. 8, no. 13, pp. 20667–20678, 2015. 
[188] G. Di Guardo, “Lipofuscin, lipofuscin-like pigments and autofluorescence,” Eur. 
J. Histochem., vol. 59, no. 1, pp. 1–2, 2015. 
[189] A. C. Croce and G. Bottiroli, “New light in flavin autofluorescence,” Eur. J. 
Histochem., vol. 59, no. 4, 2015. 
[190] B. F. Gibbs and F. H. Falcone, Basophils and Mast Cells Methods and Protocols. 
2014. 
[191] A. A. Irani, N. M. Schechter, S. S. Craig, G. DeBlois, and L. B. Schwartz, “Two 
types of human mast cells that have distinct neutral protease compositions,” Proc. 
Natl. Acad. Sci. U. S. A., vol. 83, no. 12, pp. 4464–4468, 1986. 
[192] R. Malaviya, N. J. Twesten, E. A. Ross, S. N. Abraham, and J. D. Pfeifer, “Mast 
cells process bacterial Ags through a phagocytic route for class I MHC 
presentation to T cells,” J. Immunol., vol. 156, no. 4, pp. 1490–1496, 1996. 
[193] S. Lipski, J. Grabbe, and B. M. Henz, “Absence of MHC class II antigen on mast 
cells at sites of inflammation in human skin,” Exp. Dermatol., vol. 5, no. 2, pp. 
120–124, 1996. 
[194] D. W. Van Pelt, L. M. Guth, A. Y. Wang, and J. F. Horowitz, “Factors regulating 
subcutaneous adipose tissue storage, fibrosis, and inflammation may underlie low 
fatty acid mobilization in insulin-sensitive obese adults,” Am. J. Physiol. - 
Endocrinol. Metab., vol. 313, no. 4, pp. E429–E439, 2017. 
[195] F. Louwen, A. Ritter, N. N. Kreis, and J. Yuan, “Insight into the development of 
obesity: Functional alterations of adipose-derived mesenchymal stem cells,” Obes. 
Rev., 2018. 
 
 
[196] A. Ritter, A. Friemel, N.-N. Kreis, S. C. Hoock, S. Roth, U. Kielland-Kaisen, D. 
Brüggmann, C. Solbach, F. Louwen, and J. Yuan, “Primary Cilia Are 
Dysfunctional in Obese Adipose-Derived Mesenchymal Stem Cells,” Stem Cell 
Reports, vol. 10, no. 2, pp. 583–599, 2018. 
[197] L. M. Pérez, B. de Lucas, V. V. Lunyak, and B. G. Gálvez, “Adipose stem cells 
from obese patients show specific differences in the metabolic regulators vitamin 
D and Gas5,” Mol. Genet. Metab. Reports, vol. 12, no. May, pp. 51–56, 2017. 
[198] N. Gaudenzio, N. Espagnolle, L. T. Mars, R. Liblau, S. Valitutti, and E. Espinosa, 
“Cell-cell cooperation at the T helper cell / mast cell immunological synapse,” 
Blood, vol. 114, no. 24, pp. 4979–4988, 2009. 
[199] R. Joulia, N. Gaudenzio, M. Rodrigues, J. Lopez, N. Blanchard, S. Valitutti, and E. 
Espinosa, “Mast cells form antibody-dependent degranulatory synapse for 
dedicated secretion and defence,” Nat. Commun., vol. 6, p. 6174, 2015. 
 
 
135 
[200] F. Della Rovere, A. Granata, and G. Basile, “Phagocytosis of Cancer Cells by 
Mast Cells in Breast Cancer,” vol. 3162, pp. 3157–3161, 2009. 
[201] S. J. Galli and N. Gaudenzio, “Human mast cells as antigen-presenting cells: When 
is this role important in vivo?,” J. Allergy Clin. Immunol., vol. 141, no. 1, pp. 92–
93, 2018. 
[202] S. Lotfi-Emran, B. R. Ward, Q. T. Le, A. L. Pozez, M. H. Manjili, J. A. Woodfolk, 
and L. B. Schwartz, “Human mast cells present antigen to autologous CD4+T 
cells,” J. Allergy Clin. Immunol., vol. 141, no. 1, p. 311–321.e10, 2018. 
[203] K. M. Huntoon, L. Russell, E. Tracy, K. W. Barbour, Q. Li, P. A. Shrikant, F. G. 
Berger, L. A. Garrett-Sinha, and H. Baumann, “A unique form of haptoglobin 
produced by murine hematopoietic cells supports B-cell survival, differentiation 
and immune response,” Mol. Immunol., vol. 55, no. 3–4, pp. 345–354, 2013. 
[204] J. R. Delanghe, M. R. Langlois, and M. L. De Buyzere, “Haptoglobin 
polymorphism: A key factor in the proatherogenic role of B cells?,” 
Atherosclerosis, vol. 217, no. 1, pp. 80–82, 2011. 
[205] M. Arredouani, P. Matthys, A. Kasran, H. Baumann, and J. L. Ceuppens, 
“Haptoglobin and the Th1/Th2 balance: Hints from in vitro and in vivo studies,” 
Redox Rep., vol. 6, no. 6, pp. 369–371, 2001. 
[206] S.-K. Oh, N. Pavlotsky, and A. I. Tauber, “Specific binding of haptoglobin to 
human neutrophils and its functional consequences,” J. Leukoc. Biol., vol. 47, no. 
2, pp. 142–148, 1990. 
[207] S. M. El-Ghmati, M. Arredouani, E. M. Van Hoeyveld, J. L. Ceuppens, and E. A. 
M. Stevens, “Haptoglobin interacts with the human mast cell line HMC-1 and 
inhibits its spontaneous proliferation,” Scand. J. Immunol., vol. 55, no. 4, pp. 352–
358, 2002. 
[208] K. Theilgaard-Mönch, L. C. Jacobsen, M. J. Nielsen, T. Rasmussen, L. Udby, M. 
Gharib, P. D. Arkwright, A. F. Gombart, J. Calafat, S. K. Moestrup, B. T. Porse, 
and N. Borregaard, “Haptoglobin is synthesized during granulocyte differentiation, 
stored in specific granules, and released by neutrophils in response to activation,” 
Blood, vol. 108, no. 1, pp. 353–361, 2006. 
[209] S. Yang, Y. Ma, Y. Liu, H. Que, C. Zhu, and S. Liu, “Elevated serum haptoglobin 
after traumatic brain injury is synthesized mainly in liver,” J. Neurosci. Res., vol. 
91, no. 2, pp. 230–239, 2013. 
[210] Y.-R. Kuo, C.-C. Chen, S. Goto, Y.-T. Huang, C.-C. Tsai, and M.-Y. Yang, 
“Proteomic analysis in serum of rat hind-limb allograft tolerance induced by 
immunosuppressive therapy with adipose-derived stem cells,” Plast. Reconstr. 
Surg., vol. 134, no. 6, pp. 1213–1223, 2014. 
[211] C.-M. Chien, Y.-W. Chen, C.-C. Chen, Y.-C. Wu, S.-H. Huang, S.-S. Lee, C.-S. 
Lai, S.-D. Lin, C.-J. Wang, and Y.-R. Kuo, “Adipose-Derived Stem Cell 
Modulation of T-Cell Regulation Correlates with Heme Oxgenase-1 Pathway 
Changes,” Plast. Reconstr. Surg., vol. 138, no. 5, pp. 1015–1023, 2016. 
 
 
 
136 
[212] D. N. Khalil, E. L. Smith, R. J. Brentjens, and J. D. Wolchok, “The future of 
cancer treatment: Immunomodulation, CARs and combination immunotherapy,” 
Nat. Rev. Clin. Oncol., vol. 13, no. 5, pp. 273–290, 2016. 
[213] I. Sagiv-Barfi, D. K. Czerwinski, S. Levy, I. S. Alam, A. T. Mayer, S. S. Gambhir, 
and R. Levy, “Eradication of spontaneous malignancy by local immunotherapy,” 
Sci. Transl. Med., vol. 10, no. 426, 2018. 
[214] J. -i. Kashiwakura, H. Yokoi, H. Saito, and Y. Okayama, “T Cell Proliferation by 
Direct Cross-Talk between OX40 Ligand on Human Mast Cells and OX40 on 
Human T Cells: Comparison of Gene Expression Profiles between Human 
Tonsillar and Lung-Cultured Mast Cells,” J. Immunol., vol. 173, no. 8, pp. 5247–
5257, 2004. 
 
